WO2014145090A1 - Biologically active molecules, conjugates thereof, and therapeutic uses - Google Patents

Biologically active molecules, conjugates thereof, and therapeutic uses Download PDF

Info

Publication number
WO2014145090A1
WO2014145090A1 PCT/US2014/029757 US2014029757W WO2014145090A1 WO 2014145090 A1 WO2014145090 A1 WO 2014145090A1 US 2014029757 W US2014029757 W US 2014029757W WO 2014145090 A1 WO2014145090 A1 WO 2014145090A1
Authority
WO
WIPO (PCT)
Prior art keywords
asparagine
alkyl
heteroaryl
aryl
heterocyclyl
Prior art date
Application number
PCT/US2014/029757
Other languages
French (fr)
Inventor
Thomas Nittoli
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201500905A priority Critical patent/EA038512B1/en
Priority to BR112015022585-3A priority patent/BR112015022585B1/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Priority to SG11201507481WA priority patent/SG11201507481WA/en
Priority to JP2016503215A priority patent/JP6847388B2/en
Priority to MA38496A priority patent/MA38496B2/en
Priority to EP21194635.5A priority patent/EP3964237A1/en
Priority to NZ710814A priority patent/NZ710814B2/en
Priority to MX2015011348A priority patent/MX2015011348A/en
Priority to EP14729755.0A priority patent/EP2968593A1/en
Priority to CN201480025356.9A priority patent/CN105188766B/en
Priority to CA2902872A priority patent/CA2902872A1/en
Priority to AU2014233385A priority patent/AU2014233385C1/en
Priority to MYPI2015002247A priority patent/MY183572A/en
Priority to KR1020157028418A priority patent/KR102306490B1/en
Priority to US14/776,668 priority patent/US10570151B2/en
Publication of WO2014145090A1 publication Critical patent/WO2014145090A1/en
Priority to IL240418A priority patent/IL240418B/en
Priority to ZA2015/05813A priority patent/ZA201505813B/en
Priority to PH12015502131A priority patent/PH12015502131A1/en
Priority to HK16100789.7A priority patent/HK1212890A1/en
Priority to US16/740,312 priority patent/US11345715B2/en
Priority to US17/733,974 priority patent/US20220332729A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D507/00—Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D505/00; Such ring systems being further condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Conjugates wherein the Ligand is connected to the Biologically Active Molecule through a linker compound.
  • the present disclosure also provides conjugate compounds in
  • compositions for use in various therapeutic applications are provided.
  • Proliferative diseases are characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death.
  • Abnormal proliferation for example, cancer, is caused by both external factors (e.g., tobacco, chemicals, radiation and infectious organisms) and internal factors (inherited mutations, immune system conditions, the mutations that occur from metabolism). These causal factors may act together or in sequence to initiate or promote abnormal proliferation. Cancer is treated by surgery, radiation, chemotherapy, hormones and immunotherapy. However, there is a need for more effective anti-proliferation drugs.
  • the ideal anti-proliferation therapy would enable targeted delivery of highly cytotoxic agents to tumor cells and would leave normal cells unaffected.
  • Conventional chemotherapeutic treatment with maytansine for example, is limited because of the toxic side-effects that arise from effects of the drug on non-cancerous cells.
  • Various approaches to targeted drug delivery have been tried, including the use of conjugates of tumor targeted probes (such as antibodies or growth factors) with toxins such as pseudomonas or diphtheria toxins, which arrest the synthesis of proteins and cells.
  • the side effects include reaction of the immune system due to non-human components of the conjugates.
  • the half-life of the drug conjugates were limited due to elimination from the circulation through renal filtration, and schematic degradation, uptake by the reticuloendothelial system (RES), and accumulation in non-targeted organs and tissues.
  • RES reticuloendothelial system
  • Another approach uses passive drug carriers such as polymers, liposomes, and polymeric micelles to take advantage of the hyper-permeability of vascular endothelia of tumor tissue.
  • Polymeric drugs and macromolecules accumulate within solid tumors due to an enhanced permeability and retention mechanism.
  • barriers of using such targeted deliveries include fast clearance of foreign particles from the blood, and technological hindrances in obtaining highly standardized, pharmaceutically acceptable drug delivery systems with the necessary specificity and selectivity for binding tumor cells.
  • L is absent or a ligand
  • L when L is a ligand, L is capable of binding to a cell or cell population;
  • a is an integer from 1 to 10;
  • Z2 and Zi are each independently absent or a spacer
  • D is a Biologically Active Molecule
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids;
  • W is absent, -0-, -S-, -CR5R6-, -NR4-;
  • R4, K5, and Re are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
  • X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
  • Y is absent, or a spacer.
  • linker-biologically active compounds represented by the following structural formula (V):
  • Z2 and Zi are each independently absent or a spacer
  • D is a Biologically Active Molecule
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids
  • W is absent, -0-, -S-, -CR 5 R ⁇ i-, -NR4-;
  • R4, R5, and R are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
  • X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
  • Y is absent, or a spacer
  • linker compounds is represented by formula (VI):
  • Z2 and Zi are each independently absent or a spacer
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids;
  • W is absent, -0-, -S-, -CR5R5-, -NR4-;
  • X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
  • A4 and A 5 are each independently -0-, -S-, -NRi 8 -, -CR 5 R 6 -;
  • Ri7 is selected from the group consisting of O, S, NRig, CR 5 ;
  • Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
  • pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2.
  • the disclosure provides compounds of formula (VI), wherein Z 2 is represented by the following structural formula:
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R 5 , 3 ⁇ 4 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the present disclosure also relates to pharmaceutical composition
  • the present disclosure also provides a method of reducing, retarding or stopping an abnormal cell growth comprising contacting the abnormal cell with a compound of formula (I), in an amount sufficient to retard, reduce or stop the abnormal cell growth, and wherein the abnormal cell growth is retarded, reduced or stopped.
  • the present disclosure also provides a method of killing a cell, comprising contacting the cell with a compound of formula (1), in an amount sufficient to kill the cell, and wherein the cell is killed.
  • the present disclosure also provides a method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I).
  • the present disclosure also provides a method of reducing tumor size, stopping tumor size increase, reducing tumor proliferation, or preventing tumor proliferation in an individual in need thereof comprising administering to the individual an effective amount of a composition to reduce tumor size, stop tumor size increase, reduce tumor proliferation, or prevent tumor proliferation, wherein the composition comprises a compound of formula (I).
  • the present disclosure also relates to precursor Biologically Active Molecule- linker compounds as represented by formula (V).
  • Compounds of formula (V) provide building blocks for conjugate compounds of formula (I).
  • compounds of formula (V) may be provided as compositions, pharmaceutical compositions and pharmaceutically acceptable salts thereof.
  • compositions comprising compounds of formula (I) and/or pharmaceutical formulations in the manufacture of a medicament for the treatment, prevention and/or amelioration of a medical disorder.
  • compositions comprising compounds of formula (I) and/or pharmaceutical formulations in the manufacture of a medicament for the treatment, prevention and/or amelioration of a tumor.
  • Figures 1-8 depict the results of cell viability assays in which various cancer cell lines were grown in vitro and treated with serial dilutions of antibodies, free drug, or antibody-drug conjugates as shown. Percent viability was determined in accordance with the methods set forth in Example 14.
  • FIG 1A shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 2, isotype control antibody conjugated to compound 3 ("Isotype Control-3"), anti-PSMA antibody conjugated to compound 3 ("PSMA-3"), and unconjugated anti-PSMA antibody ("PSMA").
  • Figure IB shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-PSMA antibody conjugated to compound 7 ("PSMA-7”), and unconjugated anti-PSMA antibody ("PSMA").
  • Figure 1C shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 25, isotype control antibody conjugated to compound 21 ("isotype Control-21 "), anti-PSMA antibody conjugated to compound 21 ("PSMA-21 11 ), and unconjugated anti-PSMA antibody ("PSMA").
  • Figure 2 shows the cell viability results of PC3/hSTEAPl cells (prostate cancer cell line expressing exogenous hSTEAPl) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-STEAPl antibody conjugated to compound 7 (“STEAP1-7”), and unconjugated anti-STEAPl antibody (“STEAP1”).
  • Isotype Control-7 isotype control antibody conjugated to compound 7
  • STEAP1-7 anti-STEAPl antibody conjugated to compound 7
  • STEAP1 unconjugated anti-STEAPl antibody
  • FIG 3 shows the cell viability results of T47D cells (breast cancer cell line) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-PRLR antibody conjugated to compound 7 ("PRLR-7”), and unconjugated anti-PRLR antibody ("PRLR").
  • Isotype Control-7 isotype control antibody conjugated to compound 7
  • PRLR-7 anti-PRLR antibody conjugated to compound 7
  • PRLR unconjugated anti-PRLR antibody
  • Figure 4 shows the cell viability results of HEK293/hEGFRvIII cells (HEK293 cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("isotype Control-7 11 ), anti-EGFRvIII antibody conjugated to compound 7 (“EGFRvIII-7”), and unconjugated anti-EGFRvIII antibody (“EGFRvIII”).
  • Figure 5 shows the cell viability results of MMT/hEGFRvIII cells (MMT cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-EGFRvIII antibody conjugated to compound 7 (“EGFRvIII-7”), and unconjugated anti-EGFRvIII antibody (“EGFRvIII”).
  • Isotype Control-7 isotype control antibody conjugated to compound 7
  • EGFRvIII-7 anti-EGFRvIII antibody conjugated to compound 7
  • EGFRvIII unconjugated anti-EGFRvIII antibody
  • Figure 6 shows the cell viability results of U251 /hEGFRvIII cells (U251 cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("fsotype Control-7"), anti-EGFRvIII antibody conjugated to compound 7 (“EGFRvIII-7”), and unconjugated anti-EGFRvIII antibody (“EGFRvIII”).
  • FIG 7, panels A and B show the cell viability results of HEK293 and U87MG cells, respectively, treated with compounds 6, 27, 29, and 31 (all unconjugated).
  • FIG 8 panels A-E show the cell viability results of HEK293, U251, C4-2, PC3 and MMT cells, respectively, treated with compounds 6, 9, 33 and 35 (all unconjugated).
  • conjugate refers to compound having a Ligand, linker and Biologically Active Molecule.
  • Illustrative examples include compounds of formula (I), (III) and (IV).
  • spacer refers to chemical building blocks of the linker used to spatially separate the Ligand from the Biologically Active Molecule and to allow for catabolism of the linker inside of cells.
  • a spacer can be represented by Zi and Z 2 .
  • macrolide refers to any Biologically Active Molecule having a macrolide ring.
  • alkyl refers to a hydrocarbon group having a general formula C n H2n + i .
  • alkyl include: methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, and the like.
  • Typical alkyl have from one to ten carbon atoms, one to nine carbon atoms, one to eight carbon atoms, one to seven carbon atoms, one to six carbon atoms, one to five carbon atoms, one to four carbon atoms, one to three carbon atoms, one to two carbon atoms or one carbon atom.
  • aryl refers to a monovalent or polycyclic aromatic hydrocarbon typically having 6 to 18 carbon atoms.
  • Example aryl include phenyl (like benzene), substituted benzenes, naphthalene, anthracene, indenyl, tetrahydronapthyl and the like.
  • alkynyl refers to a univalent aliphatic hydrocarbon radical containing a triple bond. Typical alkynyl are from two to twenty carbon atoms (and include at least one triple bond). Examples alkynyl include ethynyl, propynyl, 1-butynyl, 2- butynyl, 1-pentynyl, hexynyl and the like.
  • cycloalkyl refers to a monovalent saturated carbocyclic ring radical. Typical cycloalkyl are 3 to 7 member monocyclic ring radicals. One example of a cycloalkyl is cyclohexyl.
  • heteroaryl refers to a monovalent aromatic radical of 5 or 6 membered rings. Heteroaryl includes fused ring systems (at least one must be aromatic) that include up to 5 to 18 atoms, containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen. Illustrative heteroaryl are pyridinyl, triazolyl, furyl, pyrazinyl, thienyl, isoxazolyl, indazolyl, furazanyl, benzothiazolyl, quinazolinyl, and furopyridinyl.
  • heterocyclyl refers to saturated or partially saturated carbocyclic radical typically of 3 to 18 carbon atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
  • a heterocycyl may be a monocycle or a bicycle, for example.
  • Example heterocyclyl are pyrolidinyl,
  • salts refers to both organic and inorganic salts of the conjugate compounds described herein, e.g., compounds of formula (I), (III), (IV) and (V).
  • the salts are pharmaceutically acceptable and include:
  • pharmaceutically acceptable salts herein may include more than one charged atom in its structure as well as one or more counter ion. Preparation of conjugate compounds herein as pharmaceutically acceptable salts is well known to one of skill in the art.
  • human antibody as used herein is intended to include antibodies having variable and constant regions derived from human immunoglobulin sequences.
  • the human mAbs of the invention may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
  • human antibody as used herein, is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species have been grafted onto human FR sequences.
  • terapéuticaally effective amount refers to an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, for example, Lloyd (1 99) The Art, Science and Technology of
  • Ligands are any molecule capable of binding with some specificity to a given binding partner within a mammal where the interaction can result in a therapeutic use.
  • the Ligand is capable of binding to a cell or cell population.
  • Ligands for use herein include antibodies, lymphokines, hormones, growth factors, viral receptors, inter! eukins, or any other cell binding or peptide binding molecule or substance.
  • the Ligand is an antibody.
  • antibody refers to monoclonal antibodies, polyclonal antibodies, antibody fragments (Fab, Fab', and F(ab)2, minibodies, diabodies, tribodies, and the like), and bispecific antibodies.
  • Antibodies herein can be humanized using methods described in US Patent No. 6,596,541 and US Pulication No. 2012/0096572, each incorporated by reference in their entirety.
  • the Ligand is an antibody, it binds to an antigen binding partner that is a polypeptide and may be a transmembrane molecule (e.g., receptor) or a growth factor.
  • an antigen binding partner that is a polypeptide and may be a transmembrane molecule (e.g., receptor) or a growth factor.
  • antigens include, but are not limited to, molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alphal- antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone;
  • calcitonin luteinizing hormone; glucagon; clotting factors such as factor vmc, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (M1P-I- alpha); a serum albumin, such as human serum albumin; Muelleri an- inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as betalactamase; DNase; 19E;
  • ETV6-AML Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1 , -2), GD2, GD3, GloboH, glypican-3, GM3, gplOO, Her2, HLA/B-raf, HLA/EBNA1, HLA/k-ras,
  • Ligands may also include ankyrin repeat proteins, interferons, lymphokines such as IL-2 or 1L-3, hormones like insulin and glucocorticoids, growth factors such as EGF, transferrin, fibronectin type III, etc.
  • Ligands are prepared to interact with and bind to antigens defined as tumor antigens, which include antigens specific for a type of tumor or antigens that are shared, overexpressed or modified on a particular type of tumor.
  • Examples include: alpha-actinin-4 with lung cancer, ARTC1 with melanoma, BCR-ABL fusion protein with chronic myeloid leukemia, B-RAF, CLPP or Cdc27 with melanoma, CASP-8 with squamous cell carcinoma, and hsp70-2 with renal cell carcinoma as well as the following shared tumor-specific antigens, for example: BAGE-1, GAGE, GnTV, K-LC-1, MAGE-A2, NA88-A, TRP2-INT2.
  • Biologically Active Molecules herein include any molecules that have a therapeutic use in a mammal.
  • the molecule is beneficially delivered to a target within the mammal and in particular is beneficially delivered to and then within a cell (e.g., endocytosis) as compared to molecules released into the vascular or lymphatic systems.
  • Biologically Active Molecules are compounds that result in the inhibition, retardation, reduction, and/or prevention of cell growth. Biologically Active Molecules can also result in cell death via necrosis or apoptosis.
  • Illustrative Biologically Active Molecules for use in conjugate compounds described herein include: maytansinoids (e.g., DM1, DM4, etc.), auristatins (e.g., MMAE, MMAD, MMAF, etc.), duocarmycin (e.g., MGBA), dolastatin, toxoids, and other chemotherapeutically effective drugs.
  • Biologically Active Molecules that can be used in the context of the present invention include, e.g., 1-dehydrotestosterone, 2- pyrrolinodoxorubicin, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine, actinomycin D, anthracycline, anthramycin (AMC), bleomycin, busulfan, calicheamicins, carmustine cisplatin, colchicin, cyanomorpholino-doxorubicin, cyclophosphamide, cytarabine, cytochalasin B, dactinomycin, daunorubicin, decarbazine, dibromomannitol, dihydroxy anthracin dione, doxorubicin, emetine, epirubicin, ethidium bromide, etoposide, gramicidin D, glucocorticoids, lidocaine, lo
  • the Biologically Active Molecule is a maytansinoid or a maytansinoid analog.
  • Exemplary maytansinoids for use herein are described in Widdison et al., J. Med. Chem., 2006, 49, 4392-4408, incorporated by reference herein for all purposes.
  • the present disclosure includes a linker compound that is chemically capable of covalently linking two spaced chemical moieties.
  • the linker spaces and links two moieties, for example, the linker can link a Ligand and a Biologically Active Molecule.
  • the linker is self immolative wherein the linker connects two or more different chemical moieties and releases at least one of the said chemical moieties in the presence of an enzyme.
  • the linker may be attached to other chemical moieties, including but not limited to, analytical agents, biomolecules, targeting agents, detectable labels, diagnostic agents, and the like.
  • the linker attaches a Biologically Active Molecule and a Ligand.
  • the linker attaches a biologically active macrolide and a Ligand.
  • the linker attaches a biologically active macrolide and an antibody or fragments thereof.
  • the linkers are useful to covalently link ligands with therapeutic agents and markers.
  • the linkers improve chemical and/or systemic stability of the attached moieties.
  • the linkers reduce in vivo toxicity of the attached moieties.
  • the linkers improve pharmacokinetics, pharmacodynamics, and/or bioavailability of the attached moieties.
  • the linkers cleave and release a Biologically Active Molecule at a site in or near a target ceil or a cell population in a pharmacologically effective form.
  • the cleavage is performed by enzymes.
  • the cleavable groups on the linkers for the enzymatic cleavage include, but not limited to, peptide bonds, ester linkages, and disulfide linkages.
  • the linker is cleaved through pH changes.
  • linker compounds is represented by formula (VI):
  • Zz and Z 1 are each independently absent or a spacer
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CRs3 ⁇ 4-, -N3 ⁇ 4
  • X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
  • Y is absent, or
  • a 4 and A 5 are each independently -0-, -S-, -NRig-, -CR 5 R 6 -;
  • Ri7 is selected from the group consisting of O, S, NRig, CR 5 3 ⁇ 4;
  • Ri8 is selected from the group consisting of H, alkyl, aikynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, aikynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • R4, Rs, R 3 ⁇ 4 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, aikynyl, aryl, heteroaryl, or heterocyclyl;
  • pi , p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2.
  • the disclosure provides compounds of formula (VI), wherein Z 2 is represented by the following structural formula:
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, R f i and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the disclosure provides compounds of formula (VI), wherein Zi is represented by the following structural formula:
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, Rs, and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the disclosure provides compounds of formula (VI), wherein A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
  • A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
  • the disclosure provides compounds of formula (VI), wherein A is a peptide selected from the group consisting of valine-citruiline, citrulline- valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, serine- asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, as
  • the disclosure provides compounds of formula (VI), wherein X is an aryl
  • alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted
  • Rn and H are each independently H or an optionally substituted alkyl; and R s is an optionally substituted alkyl.
  • the linkers, the biologically active molecules, and other compounds of the present disclosure can be connected to an antibody or antigen-binding molecule through an attachment at a particular amino acid within the antibody or antigen-binding molecule.
  • exemplary amino acid attachments that can be used in the context of the disclosure include, e.g., lysine (see, e.g., US 5,208,020; US 2010/0129314; Hollander et al., Bioconjugate Chem,, 2008, 19:358-361; WO 2005/089808; US 5,714,586; US 2013/0101546; and US 2012/0585592), cysteine (see, e.g., US 2007/0258987; WO 2013/055993; WO 2013/055990; WO 2013/053873; WO 2013/053872; WO 2011/130598; US 2013/0101546; and US 7,750,116), selenocysteine (see,
  • Linkers can also be conjugated to an antigen-binding protein via attachment to carbohydrates (see, e.g., US 2008/0305497, and Ryan et al., Food &
  • the linkers, the biologically active molecules such as drugs can be connected to an antibody or antigen-binding molecule through an attachment at a particular amino acid within the antibody or antigen-binding molecule forming an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • the present disclosure provides Biologically Active Molecules and Ligand conjugates represented by the following structural formula (I): wherein:
  • L is absent or a Ligand
  • L when L is a Ligand, L is capable of binding to a cell or cell populati on;
  • a is an integer from 1 to 10;
  • ⁇ 2 and Z] are each independently absent or a spacer
  • D is a Biologically Active Molecule
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids;
  • W is absent, -0-, -S-, -CR5R6-, - R4-;
  • X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
  • Y is absent, , or
  • A4 and A5 are each independently -0-, -S-, -NRig-, -CR 5 R 6 -;
  • Ri 7 is selected from the group consisting of O, S, N is, CRsRg;
  • Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • R4, R5, R6 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
  • pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2.
  • the present disclosure relates to compounds where the Biologically Active Molecule is a cytotoxic biologically active macrolide.
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted; and R4, R5, Re and Rs are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the maytansinoid is represented by the following structural formula (II)(a):
  • the disclosure provides a compound of formula (I), wherein the
  • Ligand (L) is capable of binding to a specifically targeted cell population.
  • the disclosure provides a compound of formula (I), wherein the Ligand (L) is selected from the group consisting of proteins, antibodies, fragments of antibodies, nucleic acids, antigen binding scaffolds, and carbohydrates.
  • the disclosure provides a compound of formula (1), wherein the Ligand (L) is an antibody or a fragment thereof. [0074] In one embodiment, the disclosure provides a compound of formul a (I), wherein Ligand (L) is an antibody or fragment thereof that specifically binds a tumor associated antigen,
  • the disclosure provides a compound of formula (I), wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with Z 2 .
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the disclosure provides compounds of formula (I), wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with 2 ⁇
  • the disclosure provides compounds of formula (I), wherein Zi is represented by the following structural formula:
  • alkyl, alkynyl, alkenyi, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R , R5, Rg and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyi, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the disclosure provides compounds of formula (I), wherein the Biologically Active Molecule (D) is covalently attached with Z ⁇ ,
  • the disclosure provides compounds of formula (1), wherein A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
  • A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
  • the disclosure provides compounds of formula (I), wherein A is a peptide selected from the group consisting of valine-citrulline, citrulline-valme, lysine- phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine- asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine- phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine- isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine- glutamic acid, citruiline-asparagine, asparagine-citrulline, alanine-asparag
  • the disclosure provides compounds of formula (I), wherein X is an aryl selected from the group consisting of
  • alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted
  • Ri3 and R14 are each independently H or an optionally substituted alkyl; and 15 is an optionally substituted alkyl.
  • Ab is an antibody or a fragment thereof
  • AA1-AA 2 is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine- asparagine, asparagine-pheny 1 alanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine;
  • a is an integer from 1 to 10;
  • q is 0 or an integer from 1 to 5;
  • Ri7 is selected from the group consisting of O, S, NRig, CR5R6;
  • Ri, R5, 3 ⁇ 4 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
  • R9, Rio, Ri i, and R !2 are each independently H, halogen, NR13R14, nitro, cyano, -OH, - Rw, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
  • Ri3 and H are each independently H or an optionally substituted alkyl; and Ru is an optionally substituted alkyl;
  • pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
  • the disclosure provides the compounds of formula (ill) wherein:
  • Rj and R3 are each independently -0-, -S-, R4, -CR 5 R 6 -;
  • R] is selected from the group consisting of O, S, NR]g, CRsRg;
  • Ri8 is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • R4, R ⁇ R ⁇ Rp, io, Ri i, R12 are each independently H or alkyl; and
  • A3 is an alkyl.
  • the disclosure provides the compounds of formula (III) represented
  • the disclosure provides the compounds of formula (IV):
  • Ab is an antibody or a fragment thereof
  • valine-citrulline citrulline- valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine- sparagine, asparagine- leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine; a is an integer from 1 to 10;
  • q is 0 or an integer from 1 to 5;
  • alkyl is H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
  • R9, Rio, R11, and j 2 are each independently H, halogen, NR13R14, nitro, cyano, -OH, - Ru, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
  • R] is selected from the group consisting of-O-, -S-, NR4, and -CR5R5-; and further wherein R4, R 5j and Re are each independently H or alkyl.
  • the disclosure provides the compounds of formula (IV) represented by the following structure (IV)(a):
  • Ab is an antibody or a fragment thereof.
  • the disclosure provides a compound of Formula (V)
  • Z 2 and Zi are each independently absent or a spacer
  • D is a Biologically Active Molecule
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino W is absent, -0-, -S-, -CR5R-6-, or -NR4S
  • X is absent, or a substituted or unsubstituted: aryl, heteroaryl, cycloalkyl, hetero
  • A4 and A5 are each independently -0-, -S-, -NRig-, -CRjRe
  • Ri7 is selected from the group consisting of O, S, NRis, CRsRe;
  • RIB is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • Rt, R5, Re and 3 ⁇ 4 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
  • pi , p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2.
  • the disclosure provides the compound of formula (V), wherein:
  • Z2 is represented by Formula (VII):
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R 5 , e and R 8 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
  • Zi is represented by Formula (Vlli): -ZjA- lB-Zic-ZiEr (VIII),
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, R , 3 ⁇ 4 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
  • A is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine- asparagine, serine-asparagine, asparagine- serine, phenyl alanine-asparagine, asparagine- phenylalanine, leucine-asparagtne, asparagine-leucine, isoleucine-asparagine, asparagine- isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine- glutamic acid, citrulline-asparagme, asparagine-citrulline, alanine-asparagine, asparagine- alanine; and
  • alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted
  • Ri3 and RH are each independently H or an optionally substituted alkyl; and R] 5 is an optionally substituted alkyl.
  • the Biologically Active Molecules (D) can optionally be a substituted maytan
  • the disclosure provides compounds of formula (V), wherein the biologically active molecule is a optionally substituted maytansinoid represented by the
  • the disclosure provides compounds of formula (V), wherein the biologically active molecule is a maytansinoid represented by the following structural formula:
  • the disclosure provides compounds of formula (V) represe (V)(d), and (V)(e):
  • the disclosure provides the compounds of formula (IX):
  • D is a Biologically Active Molecule
  • alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, 3 ⁇ 4 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
  • the disclosure provides compound of formula (IX) wherein the Biologically Active Molecule is a cytotoxic biologically active macrolide.
  • the disclosure provides compound of formula (IX) wherein the biologically active macrolide is a maytansinoid.
  • the disclosure provides compound of formula (IX) wherein the maytansinoid is represented by formula (II).
  • the disclosure provides compound of formula (IX) wherein the maytansinoid is represented by formula (II)(a).
  • the disclosure provides a compound of formula (IX) wherein IC5 0 of the compound is greater than about 10 nM.
  • the disclosure provides a compound of formula (IX) wherein the compound is about 10 fold less cytotoxic than the corresponding compound of formula (I).
  • Ab is an antibody or a fragment thereof
  • a is an integer from 1 to 10;
  • Z 2 and Zi are each independently absent or a spacer;
  • A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids;
  • W is absent, -0-, -S-, -CR5R0-, -NR4-;
  • X is absent, aryl, heteroaryl, cycioalkyl, heterocyclyl, wherein aryl, heteroaryl, cycio
  • A4 and A5 are each independently -0-, -S-, -NRig-, -CR5R6-;
  • Ri7 is selected from the group consisting of O, S, NRig, C 53 ⁇ 4;
  • ig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
  • R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
  • pi , p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2;
  • DM is represented by the following structure:
  • the disclosure provides the compound of formula (X) represented by the following structure (X)(a):
  • a is an integer from 1 to 10.
  • Ab is an antibody or a fragment thereof
  • AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulHne-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparaguie, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citralline, alanine-asparagine, asparagine-alanine;
  • a is an integer from 1 to 10;
  • alkyl, alkynyl, alkenyl, cycloailtyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
  • Ri7 is selected from the group consisting of O, S, NRis, CR 5 R 6 ;
  • R4, R5, 3 ⁇ 4 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryi, heteroaryl, and heterocyclyl;
  • Ri 3 and RH are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl;
  • pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
  • x 0, 1 or 2;
  • the disclosure provides the compound of formula (XI) represented by the following structure (XI)(a):
  • the disclosure provides the compounds of formula (I), (III), (IV) (V), and (X), wherein A is a peptide cleavable by a protease.
  • the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease.
  • the disclosure provides the compounds of formula (1), (III), (IV) (V), and (X) wherein A is a peptide cleavable by a protease expressed in tumor tissue.
  • the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease expressed in tumor tissue.
  • the disclosure provides the compounds of formula (I), (III),
  • A is a peptide cleavable by a protease further wherein the protease is a cathepsin or a plasmin.
  • the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease further wherein the protease is a cathepsin or a plasmin.
  • Embodiments herein include compositions comprising conjugate compounds of formul (I), (III), (IV), (V), (X), or (XI) as well as mixtures thereof.
  • the compound is further represented by a compound of formula (III)(a), (III)(b), (IV)(a), (V)(a),
  • Embodiments herein include compositions comprising compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) as well as mixtures thereof.
  • compositions may be pharmaceutical compositions that further include one or more pharmaceutically acceptable carriers, diluents, and/or excipients.
  • the pharmaceutical composition is the pharmaceutically acceptable salt of compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) or mixtures thereof.
  • the pharmaceutical composition is the pharmaceutically acceptable salt of compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) or mixtures thereof.
  • Suitable pharmaceutical acceptable carriers, diluents and excipients are well known in the art and can be determined by one of ordinary skill in the art as the clinical situation warrants.
  • suitable carriers, diluents and excipients include: buffers for maintenance of proper composition pH (e.g., citrate buffers, succinate buffers, acetate buffers, phosphate buffers, lactate buffers, oxalate buffers and the like), carrier proteins (e.g., human serum albumin), saline, polyols (e.g., trehalose, sucrose, xylitol, sorbitol, and the like), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxolate, and the like), antimicrobials, and antioxidants.
  • buffers for maintenance of proper composition pH e.g., citrate buffers, succinate buffers, acetate buffers, phosphate buffers, lactate buffers, oxalate buffers and the
  • compositions herein may include a second or more therapeutic agent (e.g., an adjuvant to the conjugate compounds of formula (I), (III),
  • the second therapeutic agent can be included in the same composition as the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI), or can be administered separately from the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) (by time, or type and location of administration).
  • each of the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) can be modified in such a manner that the resulting compound still retains specificity and/or activity similar to the starting compound.
  • the Biologically Active Molecule (D) of compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) can include any and all of the Biologically Active Molecules' analogues and derivatives.
  • the Biologically Active Molecules is a macrolide and further is maytansine or an analogue of maytansine as described in Widdison et al, J. Med. Chem., 2006, 49 (14), 4392-4408.
  • the disclosure provides the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) , (III) ,(IV), (X), (XI) including (IIl)(a), (III)(b) (lV)(a), (X)(a), and (XI)(a), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the disclosure provides the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) , (III) ,(IV), (V),
  • composition comprising a therapeutically effective amount of a compound of formula (V) including
  • the disclosure provides pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (IX), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the disclosure provides pharmaceutical composition
  • conjugate compounds of formula (I), (III), (IV), (X), and (XI) can be produced with various functional groups such that attachment of the Ligand (L) to the linker and thereby a Biologically Active Molecule form a covalent conjugate.
  • the Ligand specially targets the conjugate compound to the Ligand binding partner, typically a polypeptide or other like antigen.
  • the conjugate is designed to include a Ligand having a binding partner found on cells undergoing abnormal cell growth or cells involved in a proliferative disorder.
  • conjugate compounds of formula (I), (III), (IV), (X), and (XI) have been designed such that each compound's linker is catabolized inside the cell bound by the conjugate.
  • delivery of a Biologically Active Molecule through the conjugate embodiments herein allows for delivery of Biologically Active Molecules that would normally be too toxic to administer conventionally.
  • the embodiments herein allow for highly selective and specific delivery of these molecules to cells undergoing abnormal cell growth or cells involved in proliferative disorders (as compared to catabolism outside the cell, thereby releasing the biologically active compound into the blood or lymphatic system, for example).
  • the covalent conjugate compounds described herein can also be used to deliver any type of useful Biologically Active Molecule and can be selectively targeted to any type of cell population, for example, the conjugate may be used to deliver anti-proliferative drugs to cells undergoing abnormal growth or anti-viral drugs to cells infected with a virus, as long as the selected Ligand recognizes a proper cell binding partner.
  • the pharmaceutical compositions described herein are useful in inhibiting, retarding and/or preventing abnormal cell growth or in the treatment of various proliferative disorders or disease states in mammals.
  • the mammal is a human (embodiments herein will be described in relation to humans).
  • Other mammals include any mammal that can suffer from a detectable proliferative disorder, including primates, dogs, cats, horses, goats, sheep, cattle, camels, and the like.
  • the conjugate compounds of the pharmaceutical compositions are designed for selective targeting to the cells undergoing abnormal cell growth or for the treatment of the various proliferative disorders or disease states described herein.
  • embodiments herein include methods of inhibiting abnormal cell growth or treatment of a proliferative disorder in a human comprising administering to the human a therapeutically effective amount of a pharmaceutical composition described herein.
  • Administration of a therapeutically effective amount of a pharmaceutical composition described herein may be effected in different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal, or
  • the pharmaceutical compositions herein may also be administered directly to an abnormal cell growth site (directly or indirectly contacting the abnormal cell growth) by, for example, biolistic delivery (biolistic delivery of the pharmaceutical compositions herein to a lung or brain tumor, for example).
  • Dosage regiments for administration of the pharmaceutical compositions herein will be determined by the attending health care professional or other person of skill in the art as well as based on the particular clinical situation. As is well known in the pharmaceutical arts, dosages for any one human, i.e., patient, depends on a number of factors, including patient size, patient's body surface area, patient's age and general health, patient's sex, the time and route of administration, and presence of a second therapeutic agent.
  • conjugate compounds of formula (I), (III), (IV), (X), and/or (XI) may be present in amounts between 1 ⁇ g and 100 mg/kg body weight per dose (note that where continuous infusion is considered as an administration route, as little as 1 pg/kg body weight per minute may be considered).
  • Pharmaceutical compositions can be administered one or more times a day and over a period of days, weeks, months, or years.
  • Treatment of proliferative disorder or disease includes methods of reducing a tumor size, causing necrosis or apoptosis in a tumor, killing a tumor, stopping a tumor from increasing in size and/or preventing invasiveness or metastasis of a tumor.
  • Examples of medical conditions that can be treated according to methods of inhibiting abnormal cell growth, or treating proliferative disorders include: malignancy of any type, e.g., cancer of the lung, colon, prostate, kidney, pancreas, liver, ovary, skin, lymphoma, leukemia and the like; autoimmune diseases, e.g., systemic lupus, rheumatoid arthritis, multiple sclerosis; viral infections, e.g., CMV infection, HIV infection, AIDS, Hepatitis, HPV infection; pain; mental disorders; and inflammatory diseases.
  • malignancy of any type e.g., cancer of the lung, colon, prostate, kidney, pancreas, liver, ovary, skin, lymphoma, leukemia and the like
  • autoimmune diseases e.g., systemic lupus, rheumatoid arthritis, multiple sclerosis
  • viral infections e.g., CMV infection, HIV infection, AIDS, Hepatitis, HPV
  • compositions described herein are also useful in the prevention or treatment of viral infections, pain, inflammatory diseases, autoimmune diseases, and the like in a mammal.
  • the disclosure provides a method of reducing, retarding or stopping an abnormal cell growth comprising contacting the abnormal cell with a compound of formula (I), (III) (IV), (X), and/or (XI) in an amount sufficient to retard, reduce or stop the abnormal cell growth, and wherein the abnormal cell growth is retarded, reduced or stopped.
  • the disclosure provides a method of killing a cell, comprising contacting the cell with a compound of formula (I), (III), (IV), (X), and/or (XI) in an amount sufficient to kill the cell, and wherein the cell is killed.
  • the disclosure provides a method of killing a cell, comprising contacting the cell with a compound of formula (I), (III), (IV), (X), and/or (XI) in an amount sufficient to kill the cell, and wherein the cell is killed and further wherein the cell is a tumor cell.
  • the disclosure provides a method of treatment of a medical disorder in an indi idual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI).
  • the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (V), (IX), (X), and/or (XI).
  • the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy.
  • the disclosure provides methods, wherein additional therapy is radiation therapy, chemotherapy, or a combination of both.
  • the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy and administering at least one additional therapeutic agent.
  • the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy or administering at least one additional therapeutic agent.
  • the medical disorder treated is selected from tumors, cancers, infectious diseases, neurodegenerative diseases, bone disorders, and cardiovascular diseases.
  • Embodiments herein also provide methods of preparing compounds of formula (I) from precursor or building block compounds of formula (V).
  • the compounds of formula (V) can also be used in therapeutic application where the compound of formula (V) is a pharmaceutical composition.
  • compounds of formula (V) can be included in any of the compositions or pharmaceutical compositions of compound (I), (III), (IV), (IX), (X), and/or (XI).
  • embodiments herein may include mixtures of compounds as represented by formula (I), (III), (IV), (V), (IX), (X), and/or (XI).
  • the Ligand-Biologically Active Molecule conjugate compounds can be generated by any technique known to the skilled artisan.
  • the Ligand-Biologically Active Molecule conjugate compounds comprise a Ligand unit, a Biologically Active Molecule, and optionally a Linker that joins the Biologically Active Molecule and the Ligand.
  • the covalent attachment of Biologically Active Molecules and/or Linkers to the Ligand can be accomplished using variety of reactions using the amino acid residues of the Ligand, e.g., antibody, including the amine groups of lysine, the free carboxylic acid groups of glutamic and aspartic acid, the sulfhydryl groups of cysteine and the various moieties of the aromatic amino acids.
  • conjugates in accordance with various embodiments described herein can be prepared by any known method in the art.
  • An illustrative protocol for producing conjugates is provided in the Examples below.
  • other known methods can be used, including, for example, protocols described in WO 2009/134977, US Patent No. 7,81 ,572 and US Patent No. 6,441,163, as long as the protocols are used to prepare the compounds as described herein. These references are incorporated by reference for their intended purpose.
  • the conjugates can be prepared by i) reacting a Ligand with Linker to form a modified Ligand-Linker compound; ii) optionally purifying the Ligand- Linker compound; iii) conjugating a Biologically Active Molecule, e.g., a macrolide, to the Ligand-Linker to form a conjugate of formula (I), (III), (IV), (X), or (XI); and iv) purifying the conjugate.
  • a Biologically Active Molecule e.g., a macrolide
  • the conjugates can be prepared by reacting a Biologically Active Molecule with a first component of the Linker (Zi), followed by successive reactions to build out the Linker, including addition of Y, X, W, A and Z 2 , or any combination thereof.
  • the conjugates are prepared by reacting a Ligand, Linker and biologically active macrolide in a single reaction. Once the conjugates in accordance with the invention are prepared they can be purified.
  • the conjugate compounds described herein can be evaluated for their ability to suppress proliferation of various cancer cell lines in vitro.
  • the in vitro cytotoxicity assays can be conducted using methods known in the art (see Widdison et al., J. Med. Chem., 2006, 49(14), 4392-408) and as illustrated in Example 7 herein.
  • conjugate compounds can be applied to in vitro plated cancer cells for a predetermined number of days and surviving cells measured in assays by known methods. Proper controls can be utilized to ensure validity of results as can IC5 0 values. Examples of in vitro potency of conjugate compounds herein can be seen in Figures 1 and 2.
  • Proton NMR spectra (for compounds that could not be detected by UV) were acquired on a Varian Inova 300 MHz instrument, while mass spectra were collected on an Agilent 1100 series LC/MSD with electrospray ionization source and triple-quad ion trap analyzer. Appropriate conjugates were analyzed using a Bruker ultraFleXtreme MALDI- TOF-TOF mass spectrometer. All starting materials and solvents were purchased commercially and used without purification, unless otherwise noted.
  • Step 1 Maytansin-3 -N-m ethyl-L ⁇ lan ine (2)
  • Step 2 Maytansin-3-N-methyl-L-(S) ⁇ alanine-N-[ 4- (amino-citrulline-valine- hexanam ide-6-maleim idyl) benzyl] carbarn ate (3):
  • Step 1 N-tert-Butoxycarbonyl-beta-alanine succinate ester (4)
  • Step 2 Mayt nsin-3-N-methyl-L-(S)-alanine-Boc-fi-Ala (5)
  • Step 3 Maytansm-3-N-jnethyl-L-(S)-alanine-fi-Ala (6)
  • Step 4 Maytansin-3-N-methyl-L-(S)-alanine-propanamidyl-3-N-7nethyl ⁇ N-[4' (ainino ⁇ cit ⁇ -unine-valine ⁇ exanamide-6-maleimidyl)benzylJcai'bamate (7)
  • Step 1 3-Methyldithio-propionic acid succinate ester (8)
  • Step 2 Maytansin-3-N- ethyl-L-(S)-alaninepropanamidyl-3-methyldisulfide
  • Step 3 Maytansin-3-N-methyl-L-(S)-alanine-propanamide-3-ihiol (10)
  • the title compound was prepared using a modified version of the method described by Whitesides et al. (J. Org. Chem., 1991, 56, 2648-2650).
  • the product of the preceding step (9, 2,42 g, 3.09 mmol) was dissolved in acetonitrile (30 mL), treated with a solution of tris(2-carboxyethyl)phosphine hydrochloride (8.23 g, 28.7 mmol) in water (30 mL), the pH raised to 3 with the addition of saturated aqueous NaHCOj (5 mL), the f!ask purged with Ar, and the reaction stirred at ambient temperature under a rubber septum (vented due to effervescence).
  • Step 4 4 ⁇ Amino-(N-benzyloxycarbonyl)benzylamine (14)
  • 4-Aminobenzylamine (1.00 g, 8.18 mmol) and triethylamine (1.20 mL, 8.61 mmol) were dissolved in anhydrous tetrahydrofuran (THF, 10 mL) under N 2 , cooled in a brine/ice bath with stirring, and treated dropwise over 20 min with a solution of benzyl chloroformate (1.20 mL, 8.41 mmol) in anhydrous THF (10 mL).
  • the title compound was prepared as a colorless gum from commercial 6- aminocaproic acid by a method similar to that of Marnett et al. (J. Med. Chem., 1 96, 39,
  • Step 11 Maytansin-3-N-methyl-L-(S)-alanine-propanamidyl-3-N-[4-(amino- citfuUine-Boc-valine) -benzyl] -dith iocarbamate (18)
  • Step 12 Mayta in-3-N- ethyl-L-(S)-alanine-propanamidyl-3-N-[4-(amino- citrulline-valine)-benzyl]-dithiocarbamate (19)
  • Step 13 Maytansin-3-N-methyl-L-( )-alanine-propanamidyl-3-N-[4-(amino- citrulline-valine-hexanamide-6-maieimidyl)benzyl]-dithiocarbamate (21)
  • Step 3 Maytansin-3-N-methyl»L ⁇ (&)-alanine ⁇ ropanamidyl-3-N-[4- (acetamidyl) benzyl] -dithio-carbamate (25)
  • Step 3 The product of the preceding step (24, 0.093 g, 0.45 mmol) and the product of Example 3, Step 3 (10, 0.070 g, 0.095 mmol) were dissolved in acetonitrile (MeCN, 2 mL) and dry DMF (1 mL), and treated with basic alumina (activated, Brockniann I, 0.357 g).
  • Step 1 Maytmsin-3-N-methyl-L-(S)-alanine-N-carboxy-6-[3,4-dihydro-2-(tert- butoxycarbonyl) -lH-isoquinoline ]
  • Step 2 Maytamin-3-N-methy!-L-fi)-alanine-N-carboxy-6-(l, 2,3,4- tetrahydroisoquinoline) (33)
  • Step 1 Maytansm-3-N-methyl-L-(S)-alanine- N-carboxy-4-fl-(tert- butoxycarbonyl) -piperidine ]
  • the title compound was prepared as a white solid (0.027 g, 46%) from maytan- 3-N-methyl-L-(5)-alanine (2, 0.045 g, 0.069 mmol) and commercial 1-t- butoxycarbonylpiperidine-4-carboxylic acid (34, 0.024 g,0.105 mmol) by the method of Example 8, Step 1.
  • Step 2 Maytansin-3-N-methyl-L-(&)-alanine- N-carboxy-4-piperidine (35)
  • Step 1 Maytansin- 3 -N-methyl-L-(S) -alanine- N-methyl-beta-alanine-N-[4- (tert-butoxycarbonyl-valine-citrultine-amino)benzyloxy]-carbamate
  • Step 2 Maytansin-3-N-methyl-L-(&)-alanine- N-methyl-beta-alanine-N-[4- (valine-cUrulline-amino)benzyloxy]-carbamate (37)
  • Step 3 Maytansin- 3 -N-methyl-L-(&) -alanine- N-methyl-beta-alanine-N-[4- (4- ⁇ isothiocyanato-phenyl ⁇ -thioureido-vali -citrulline-amino )benzyloxy] -carbamate (39)
  • Step 1 l-(4-Arnino ⁇ butyl)-maleirnide
  • Step 2 l-(4-Isothiocyanato-butyl)-maleimide (41)
  • Step 3 Maytansin-3-N-methyl-L-(S)-alanme ⁇ N-methyl-beta-alanine-N ⁇ [4- (4- ⁇ maleimidylbutylj-thioureido-valine-citrullin ⁇ (42)
  • the four antibodies used in these experiments were: (1) a PSMA antibody having the heavy and light chain variable domains of clone AB-PG1-XG 1-006 as set forth in WO 2007002222A2, (2) a STEAP1 antibody having the heavy and light chain variable domains of clone mul20, expressed as a hlgGl, as set forth in WO 2008052187A2, (3) an EGFRvIII antibody having the heavy and light chain variable domains of clone 131 as set forth in WO2013075048A1, and (4) a PRLR having the heavy and light chain variable domains of clone H1H6953N as set forth in US Application Serial No.
  • OD450 levels CC 8
  • nuclear counts from digitonin (40 nM) treated cells were subtracted from all wells and viability is expressed as a percentage of the untreated controls.
  • IC50 values were determined from a four- parameter logistic equation over a 10-point response curve (GraphPad Prism). All curves and IC50 values are corrected for payload equivalents.
  • the maytansinoid conjugate STEAP1-7 In PC3/hSTEAPl cells (prostate cancer line), expressing hSTEAPl at 352 fold above isotype control binding, the maytansinoid conjugate STEAP1-7 possesses an IC 50 value of 4 nM ( Figure 2). The naked STEAP1 antibody was devoid of any anti-proliferation activity.
  • T47D cells In T47D cells (breast cancer line), natively expressing PRLR at 14 fold above isotype control binding, the maytansinoid conjugate PRLR-7 possesses an IC50 value of 1 ,0 nM ( Figure 3). The naked T47D antibody was devoid of any anti-proliferation activity.
  • the maytansinoid conjugate EGFRvIII-7 possesses an IC50 value of 0.4 nM ( Figure 4).
  • the naked EGFRvIII antibody was devoid of any anti-proliferation activity.
  • the maytansinoid conjugate EGFRvIII-7 possesses an IC50 value of 0.3 nM ( Figure 5).
  • the naked EGFRvIII antibody was devoid of any anti-proliferation activity.
  • Anti-EGFRvIII Antibody Drug Conjugates are Potent Inhibitors of Tumor Growth in in vivo EGFRvIII Positive Breast Cancer Allograft Models
  • H1H1863N2 comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: l; a light chain variable region (LCVR) comprising SEQ ID NO:5; heavy chain complementarity determining regions (HCDRl , HCDR2 and HCDR3) comprising SEQ ID NOs: 2, 3 and 4, respectively; and light chain complementarity determining regions (LCDR1 , LCDR2 and LCDR3) comprising SEQ ID NOs: 6, 7 and 8, respectively.
  • HCVR heavy chain variable region
  • LCVR light chain variable region
  • LCVR light chain variable region
  • LCVR heavy chain complementarity determining regions
  • LCDR1 , LCDR2 and LCDR3 comprising SEQ ID NOs: 6, 7 and 8, respectively.
  • a first ADC was produced by conjugating H1H1863N2 to the maytansinoid DM1 via a non-cleavable MCC linker ⁇ see, e.g., US 5,208,020 and US application
  • H1H1863N2-MCC-DM1 A second ADC was produced by conjugating H1H1863N2 to 7 to yield "H1H1863N2-7.”
  • H1H1863N2- MCC-DM1 exhibited an IC 50 of 12 nM whereas H1H1863N2-7 exhibited an IC 5 o of only 0.8 nM.
  • the anti-EGFRvIII ADC H1H1863N2-7 exhibited much more potent tumor cell killing ability than the corresponding antibody conjugated to DM1 via an MCC linker.
  • mice bearing EGFRvIII positive breast cancer allografts were established by subcutaneous implantation of 0.5xl0 6 MMT/EGFRvlII cells into the left flank of female CB17 SCID mice (Taconic, Hudson, NY). Once tumors had reached an average volume of 140 mm 3 ( ⁇ Day 8), mice were randomized into groups of seven, and dosed with anti-EGFRvIII ADCs using either the MCC-DMl or 7 linker-drug format.
  • Control reagents including non-binding ADCs using either the MCC-DMl or 7 linker-drug format, and PBS vehicle were also assessed.
  • ADCs were dosed at 1 and 5 mg kg three times over one week and thereafter monitored until an average tumor size of approximately 2000 mm 3 was attained in the group administered with vehicle alone. At this point the Tumor Growth Inhibition was calculated.
  • tumor size relative to the vehicle treated group were calculated as follows: tumors were measured with calipers twice a week until the average size of the vehicle group reached 1000mm 3 ; tumor size was calculated using the formula (length x width 2 )/2. Tumor growth inhibition was calculated according to the following formula: (1- (( fi n a]-Ti t ,i t jai)/(C f i n ai-Ci I ,jti a i)))* 100 5 where T (treated group) and C (control group) represent the mean tumor mass on the day the vehicle group reached 1000mm 3 . Results are summarized in Table 3.
  • Table 3 Tumor Size and Tumor Growth Inhibition Following Administration of Anti- EGF vIII Antibody-Drug Conjugates and Controls, administered in repeat dose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule -ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

Description

Biologically Active Molecules, Conjugates Thereof, and Therapeutic Uses
TECHNICAL FIELD
[0001] The present disclosure provides Ligand-Biologically Active Molecule
Conjugates wherein the Ligand is connected to the Biologically Active Molecule through a linker compound. The present disclosure also provides conjugate compounds in
pharmaceutical compositions for use in various therapeutic applications.
BACKGROUND OF THE INVENTION
[0002] Proliferative diseases are characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Abnormal proliferation, for example, cancer, is caused by both external factors (e.g., tobacco, chemicals, radiation and infectious organisms) and internal factors (inherited mutations, immune system conditions, the mutations that occur from metabolism). These causal factors may act together or in sequence to initiate or promote abnormal proliferation. Cancer is treated by surgery, radiation, chemotherapy, hormones and immunotherapy. However, there is a need for more effective anti-proliferation drugs.
[0003] The ideal anti-proliferation therapy would enable targeted delivery of highly cytotoxic agents to tumor cells and would leave normal cells unaffected. Conventional chemotherapeutic treatment, with maytansine for example, is limited because of the toxic side-effects that arise from effects of the drug on non-cancerous cells. Various approaches to targeted drug delivery have been tried, including the use of conjugates of tumor targeted probes (such as antibodies or growth factors) with toxins such as pseudomonas or diphtheria toxins, which arrest the synthesis of proteins and cells. However, the side effects include reaction of the immune system due to non-human components of the conjugates. Further, the half-life of the drug conjugates were limited due to elimination from the circulation through renal filtration, and schematic degradation, uptake by the reticuloendothelial system (RES), and accumulation in non-targeted organs and tissues.
[0004] Another approach uses passive drug carriers such as polymers, liposomes, and polymeric micelles to take advantage of the hyper-permeability of vascular endothelia of tumor tissue. Polymeric drugs and macromolecules accumulate within solid tumors due to an enhanced permeability and retention mechanism. However, barriers of using such targeted deliveries include fast clearance of foreign particles from the blood, and technological hindrances in obtaining highly standardized, pharmaceutically acceptable drug delivery systems with the necessary specificity and selectivity for binding tumor cells.
[0005] Thus, a need exists for targeted anti-proliferative compounds.
SUMMARY OF THE INVENTION
[0006] The present disclosure relates to conjugate compounds represented by the follow
Figure imgf000003_0001
(I)
wherein:
L is absent or a ligand;
further wherein:
when L is a ligand, L is capable of binding to a cell or cell population;
a is an integer from 1 to 10;
Z2 and Zi are each independently absent or a spacer;
D is a Biologically Active Molecule;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R6-, -NR4-;
further wherein: R4, K5, and Re are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted; and
Y is absent, or a spacer.
[0007] The present disclosure also provides linker-biologically active compounds represented by the following structural formula (V):
Z2 A— W— Y Zy— D (V)
wherein:
Z2 and Zi are each independently absent or a spacer;
D is a Biologically Active Molecule; A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R<i-, -NR4-;
further wherein: R4, R5, and R are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted; and
Y is absent, or a spacer,
[0008] The present disclosure also provides linkers represented by the following structural formula (VI).
[0009] In one embodiment, the linker compounds is represented by formula (VI):
Z2 A— W— X Y Ζγ (VI)
wherein:
Z2 and Zi are each independently absent or a spacer;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R5-, -NR4-;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
Figure imgf000004_0001
wherein Als A3, Rj and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0 , -C(=0)-0-, -0-C(=0)-0-, -C(=0> (CHx)pl-, -C(=0)-0-(CHx)pi-, -(CHx)pl-C(=0)-, -(CHx)pi-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)P2-0-)p3-, -C(=S , -C(=S)-S-, -S-C(=S)-, -C(=S)-NH-, -S-C(=S)-S-, -S-, -SO-, -S02-, - NR4-, -N(R )-C(=0)-N(Re>5 -N(R4)-C(=0)0-, -N(R4)-C(=0 , -C(=0)-N(I )-, -C(=0)- N(R4)-C(=0 , -0-C(=0)-NR4-: wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRi8-, -CR5R6-;
Ri7 is selected from the group consisting of O, S, NRig, CR5 ;
Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
[0010] In one aspect, the disclosure provides compounds of formula (VI), wherein Z2 is represented by the following structural formula:
Figure imgf000005_0001
wherein:
Z2A, 2B, 2C and Z2D are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5Rs-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0, -0-C(=0)-0-, -C(=0)-(CHx)pl, -C(=0)-0-(CHs)pl, -(C¾)p,-C(=0)-, -(CHx)p,-C(=0)-0-, -(0-(CH2)P2-)p3-, -(((¾)ρ2-0-)ρ3-, - C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S>, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -NCR,)- C(=0)-N(R8)-, -N(R4)-C(=0)0, -N(R4)-C(=0)-, -C(=0)-N(R4 , -C(=0)-N(R4)-C(=0)-, -O- 0
C(=0)-N(R4), -0-C(=S)-N(R4)-, -C(=S)-N(R4)-, -N=C=S, -N=C=0, & or
Figure imgf000005_0002
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, ¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0011] The present disclosure also relates to pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[0012] The present disclosure also provides a method of reducing, retarding or stopping an abnormal cell growth comprising contacting the abnormal cell with a compound of formula (I), in an amount sufficient to retard, reduce or stop the abnormal cell growth, and wherein the abnormal cell growth is retarded, reduced or stopped.
[0013] The present disclosure also provides a method of killing a cell, comprising contacting the cell with a compound of formula (1), in an amount sufficient to kill the cell, and wherein the cell is killed.
[0014] The present disclosure also provides a method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I).
[0015] The present disclosure also provides a method of reducing tumor size, stopping tumor size increase, reducing tumor proliferation, or preventing tumor proliferation in an individual in need thereof comprising administering to the individual an effective amount of a composition to reduce tumor size, stop tumor size increase, reduce tumor proliferation, or prevent tumor proliferation, wherein the composition comprises a compound of formula (I).
[0016] The present disclosure also relates to precursor Biologically Active Molecule- linker compounds as represented by formula (V). Compounds of formula (V) provide building blocks for conjugate compounds of formula (I). In addition, compounds of formula (V) may be provided as compositions, pharmaceutical compositions and pharmaceutically acceptable salts thereof.
[0017] The present disclosure further includes the use of any of the compositions comprising compounds of formula (I) and/or pharmaceutical formulations in the manufacture of a medicament for the treatment, prevention and/or amelioration of a medical disorder.
[0018] The present disclosure further includes the use of any of the compositions comprising compounds of formula (I) and/or pharmaceutical formulations in the manufacture of a medicament for the treatment, prevention and/or amelioration of a tumor.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figures 1-8 depict the results of cell viability assays in which various cancer cell lines were grown in vitro and treated with serial dilutions of antibodies, free drug, or antibody-drug conjugates as shown. Percent viability was determined in accordance with the methods set forth in Example 14.
[0020] Figure 1A shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 2, isotype control antibody conjugated to compound 3 ("Isotype Control-3"), anti-PSMA antibody conjugated to compound 3 ("PSMA-3"), and unconjugated anti-PSMA antibody ("PSMA").
[0021] Figure IB shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-PSMA antibody conjugated to compound 7 ("PSMA-7"), and unconjugated anti-PSMA antibody ("PSMA").
[0022] Figure 1C shows the cell viability results of C4-2 cells (prostate cancer cell line) treated with compound 25, isotype control antibody conjugated to compound 21 ("isotype Control-21 "), anti-PSMA antibody conjugated to compound 21 ("PSMA-2111), and unconjugated anti-PSMA antibody ("PSMA").
[0023] Figure 2 shows the cell viability results of PC3/hSTEAPl cells (prostate cancer cell line expressing exogenous hSTEAPl) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-STEAPl antibody conjugated to compound 7 ("STEAP1-7"), and unconjugated anti-STEAPl antibody ("STEAP1").
[0024] Figure 3 shows the cell viability results of T47D cells (breast cancer cell line) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-PRLR antibody conjugated to compound 7 ("PRLR-7"), and unconjugated anti-PRLR antibody ("PRLR").
[0025] Figure 4 shows the cell viability results of HEK293/hEGFRvIII cells (HEK293 cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("isotype Control-711), anti-EGFRvIII antibody conjugated to compound 7 ("EGFRvIII-7"), and unconjugated anti-EGFRvIII antibody ("EGFRvIII").
[0026] Figure 5 shows the cell viability results of MMT/hEGFRvIII cells (MMT cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("Isotype Control-7"), anti-EGFRvIII antibody conjugated to compound 7 ("EGFRvIII-7"), and unconjugated anti-EGFRvIII antibody ("EGFRvIII").
[0027] Figure 6 shows the cell viability results of U251 /hEGFRvIII cells (U251 cells expressing exogenous hEGFRvIII) treated with compound 6, isotype control antibody conjugated to compound 7 ("fsotype Control-7"), anti-EGFRvIII antibody conjugated to compound 7 ("EGFRvIII-7"), and unconjugated anti-EGFRvIII antibody ("EGFRvIII").
[0028] Figure 7, panels A and B show the cell viability results of HEK293 and U87MG cells, respectively, treated with compounds 6, 27, 29, and 31 (all unconjugated).
[0029] Figure 8, panels A-E show the cell viability results of HEK293, U251, C4-2, PC3 and MMT cells, respectively, treated with compounds 6, 9, 33 and 35 (all unconjugated).
DETAILED DESCRIPTION
[0030] The references to certain embodiments made in the following description are considered illustrative only of the principles of the disclosure. Further, since numerous modifications and changes will readily be apparent to those skilled in the art, it is not intended to limit the disclosure to the exact construction and process shown as described herein. Accordingly, all suitable modifications and equivalents may be resorted to as falling within the scope of the disclosure and as defined by the claims that follow.
[0031] The words "comprise", "comprising", "include" and "including" when used in this specification and in the following claims are intended to specify the presence of the stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more additional features, integers, components, or steps thereof.
[0032] General terms used in any of the embodiments herein can be defined as follows; however, the meaning stated should not be interpreted as limiting the scope of the term per se.
[0033] The term "conjugate" as used herein refers to compound having a Ligand, linker and Biologically Active Molecule. Illustrative examples include compounds of formula (I), (III) and (IV).
[0034] The term "spacer" as used herein refers to chemical building blocks of the linker used to spatially separate the Ligand from the Biologically Active Molecule and to allow for catabolism of the linker inside of cells. A spacer can be represented by Zi and Z2.
[0035] The term "macrolide" as used herein refers to any Biologically Active Molecule having a macrolide ring.
[0036] The term "alkyl" as used herein refers to a hydrocarbon group having a general formula CnH2n +i. Examples of alkyl include: methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, and the like. Typical alkyl have from one to ten carbon atoms, one to nine carbon atoms, one to eight carbon atoms, one to seven carbon atoms, one to six carbon atoms, one to five carbon atoms, one to four carbon atoms, one to three carbon atoms, one to two carbon atoms or one carbon atom.
[0037] The term "aryl" as used herein refers to a monovalent or polycyclic aromatic hydrocarbon typically having 6 to 18 carbon atoms. Example aryl include phenyl (like benzene), substituted benzenes, naphthalene, anthracene, indenyl, tetrahydronapthyl and the like.
[0038] The term "alkenyl" as used herein refers to an aliphatic linear or branched monovalent hydrocarbon radical of two or more carbon atoms with at least one site of unsaturation. Alkenyl have a general formula of R.2C=CR.2. Examples of alkenyl include: ethylenyl, vinyl, allyl, and the like.
[0039] The term "alkynyl" as used herein refers to a univalent aliphatic hydrocarbon radical containing a triple bond. Typical alkynyl are from two to twenty carbon atoms (and include at least one triple bond). Examples alkynyl include ethynyl, propynyl, 1-butynyl, 2- butynyl, 1-pentynyl, hexynyl and the like.
[0040] The term "cycloalkyl" as used herein, refers to a monovalent saturated carbocyclic ring radical. Typical cycloalkyl are 3 to 7 member monocyclic ring radicals. One example of a cycloalkyl is cyclohexyl.
[0041] The term "heteroaryl" as used herein, refers to a monovalent aromatic radical of 5 or 6 membered rings. Heteroaryl includes fused ring systems (at least one must be aromatic) that include up to 5 to 18 atoms, containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen. Illustrative heteroaryl are pyridinyl, triazolyl, furyl, pyrazinyl, thienyl, isoxazolyl, indazolyl, furazanyl, benzothiazolyl, quinazolinyl, and furopyridinyl.
[0042] The term "heterocyclyl" as used herein refers to saturated or partially saturated carbocyclic radical typically of 3 to 18 carbon atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur. A heterocycyl may be a monocycle or a bicycle, for example. Example heterocyclyl are pyrolidinyl,
tetrahydrofuranyl, dihydropyranyl, thtoxanyl, 2H-pyranyl, dioxanyl, dithianyl, piperidino, and the like.
[0043] The phrase "pharmaceutically acceptable salt" as used herein refers to both organic and inorganic salts of the conjugate compounds described herein, e.g., compounds of formula (I), (III), (IV) and (V). The salts are pharmaceutically acceptable and include:
sulfate, citrate, nitrate, phosphate, ascorbate, bromide, gluconate, benzoate, oxalate, pantothenate, and the like. Note that pharmaceutically acceptable salts herein may include more than one charged atom in its structure as well as one or more counter ion. Preparation of conjugate compounds herein as pharmaceutically acceptable salts is well known to one of skill in the art.
[0044] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human immunoglobulin sequences. The human mAbs of the invention may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species have been grafted onto human FR sequences.
[0045] The term "therapeutically effective amount" as used herein refers to an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, for example, Lloyd (1 99) The Art, Science and Technology of
Pharmaceutical Compounding).
Ligands and Binding Partners
[0046] The effectiveness of the conjugate compound embodiments described herein depend on the selectivity of the Ligand to bind its ligand binding partner.
[0047] In one embodiment, Ligands are any molecule capable of binding with some specificity to a given binding partner within a mammal where the interaction can result in a therapeutic use. In some aspects the Ligand is capable of binding to a cell or cell population.
[0048] Ligands for use herein include antibodies, lymphokines, hormones, growth factors, viral receptors, inter! eukins, or any other cell binding or peptide binding molecule or substance.
[0049] In one embodiment the Ligand is an antibody. As defined herein, antibody refers to monoclonal antibodies, polyclonal antibodies, antibody fragments (Fab, Fab', and F(ab)2, minibodies, diabodies, tribodies, and the like), and bispecific antibodies. Antibodies herein can be humanized using methods described in US Patent No. 6,596,541 and US Pulication No. 2012/0096572, each incorporated by reference in their entirety.
[0050] Where the Ligand is an antibody, it binds to an antigen binding partner that is a polypeptide and may be a transmembrane molecule (e.g., receptor) or a growth factor.
Exemplary antigens include, but are not limited to, molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alphal- antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone;
calcitonin; luteinizing hormone; glucagon; clotting factors such as factor vmc, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (M1P-I- alpha); a serum albumin, such as human serum albumin; Muelleri an- inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as betalactamase; DNase; 19E; a cytotoxic T-lymphocyte associated antigen (CTLA), such as CTLA-4; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT4, NT-5, or NT-6), or a nerve growth factor such as NGF-β; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; fibroblast growth factor receptor 2 (FGFR2), epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF-βΙ, TGF^2, TGF- β3, TGF- 4, or TGF- β5; insulin-like growth factor-1 and -II (IGF-1 and IGF-II); des(I-3)-IGF-l (brain IGF-1), insulin-like growth factor binding proteins, EpCAM, GD3, FLT3, PSMA, PSCA, MUCI, UCI6, STEAP, CEA, TENB2, EphA receptors, EphB receptors, folate receptor, FOLRI, mesothelin, cripto, alphavbeta6, integrins, VEGF, VEGFR, EGFR, transferrin receptor, IRTAI, 1RTA2, 1RTA3, 1RTA4, 1RTA5; CD proteins such as CD2, CD3, CD4, CD5, CD6, CD8, CDII, CDI4, CDI9, CD20, CD21, CD22, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD59, CD70, CD79, CD80. CD81, CD103, CD105, CD134, CD137, CD 138, CDI52, or an antibody which binds to one or more tumor-associated antigens or cell-surface receptors disclosed in US Publication No.
2008/0171040 or US Publication No. 2008/0305044 and incorporated in their entirety by reference; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon, such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL- 10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the HIV envelope; transport proteins; homing receptors; addressins; regulatory proteins; mtegrins, such as CDlla, CDllb, CDUc, CDI8, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as AFP, ALK, B7H4, BAGE proteins, β-catenin, brc-abl, BRCAl, BORIS, CA9 (carbonic anhydrase IX), caspase- 8, CD20, CD40, CD123, CDK4, CEA, CLEC 12A, c-kit, cMET, CTLA4, cyclin-B l , CYP1B 1, EGFR, EGFRvIlI, endoglin, Epcam, EphA2, ErbB2/Her2, ErbB3/Her3,
ErbB4/Her4, ETV6-AML, Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1 , -2), GD2, GD3, GloboH, glypican-3, GM3, gplOO, Her2, HLA/B-raf, HLA/EBNA1, HLA/k-ras,
HLA MAGE-A3, hTERT, IGF 1R, LGR5, LMP2, MAGE proteins (e.g., MAGE-1 , -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-iAP, Mucl, Mucl6 (CA-125), MUM1 , NA17, NGEP, NY-BR1 , NY-BR62, NY-BR85, NY-ESOl , OX40, pi 5, p53, PAP, PAX3, PAX5, PCTA-1 , PDGFR-a, PDGFR-β, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PLAC1, PRLR, PRAME, PSCA, PSGR, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1 , Steap-2, STn, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TNFRSF17, TRP-1, TRP-2, tyrosinase, and uroplakin-3, and fragments of any of the above-listed polypeptides.
[0051] Ligands may also include ankyrin repeat proteins, interferons, lymphokines such as IL-2 or 1L-3, hormones like insulin and glucocorticoids, growth factors such as EGF, transferrin, fibronectin type III, etc.
[0052] Embodiments herein are target specific for therapeutic use. In one embodiment, Ligands are prepared to interact with and bind to antigens defined as tumor antigens, which include antigens specific for a type of tumor or antigens that are shared, overexpressed or modified on a particular type of tumor. Examples include: alpha-actinin-4 with lung cancer, ARTC1 with melanoma, BCR-ABL fusion protein with chronic myeloid leukemia, B-RAF, CLPP or Cdc27 with melanoma, CASP-8 with squamous cell carcinoma, and hsp70-2 with renal cell carcinoma as well as the following shared tumor-specific antigens, for example: BAGE-1, GAGE, GnTV, K-LC-1, MAGE-A2, NA88-A, TRP2-INT2.
Biologically Active Molecules
[0053] Biologically Active Molecules herein include any molecules that have a therapeutic use in a mammal. In typical embodiments the molecule is beneficially delivered to a target within the mammal and in particular is beneficially delivered to and then within a cell (e.g., endocytosis) as compared to molecules released into the vascular or lymphatic systems.
[0054] In one aspect, Biologically Active Molecules are compounds that result in the inhibition, retardation, reduction, and/or prevention of cell growth. Biologically Active Molecules can also result in cell death via necrosis or apoptosis. Illustrative Biologically Active Molecules for use in conjugate compounds described herein include: maytansinoids (e.g., DM1, DM4, etc.), auristatins (e.g., MMAE, MMAD, MMAF, etc.), duocarmycin (e.g., MGBA), dolastatin, toxoids, and other chemotherapeutically effective drugs.
[0055] Other specific examples of Biologically Active Molecules that can be used in the context of the present invention include, e.g., 1-dehydrotestosterone, 2- pyrrolinodoxorubicin, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine, actinomycin D, anthracycline, anthramycin (AMC), bleomycin, busulfan, calicheamicins, carmustine cisplatin, colchicin, cyanomorpholino-doxorubicin, cyclophosphamide, cytarabine, cytochalasin B, dactinomycin, daunorubicin, decarbazine, dibromomannitol, dihydroxy anthracin dione, doxorubicin, emetine, epirubicin, ethidium bromide, etoposide, gramicidin D, glucocorticoids, lidocaine, lomustine (CCNU), mechlorethamine, melphalan, methotrexate, mithramycin, mitomycin, mitoxantrone, morpholino-doxorubicin, procaine, propranolol, puromycin, pyrrolobenzodiazapines, sibiromycin, streptozotocin, taxol, tenoposide, tetracaine, thioepa chlorambucil, trichothecenes, tubulysin, vincristine, and stereoisomers, isosteres, analogs or derivatives of any of the foregoing,
[0056] In one embodiment the Biologically Active Molecule is a maytansinoid or a maytansinoid analog. Exemplary maytansinoids for use herein are described in Widdison et al., J. Med. Chem., 2006, 49, 4392-4408, incorporated by reference herein for all purposes. Linker Materials
[0057] The present disclosure includes a linker compound that is chemically capable of covalently linking two spaced chemical moieties. The linker spaces and links two moieties, for example, the linker can link a Ligand and a Biologically Active Molecule. In one aspect, the linker is self immolative wherein the linker connects two or more different chemical moieties and releases at least one of the said chemical moieties in the presence of an enzyme. In another aspect, the linker may be attached to other chemical moieties, including but not limited to, analytical agents, biomolecules, targeting agents, detectable labels, diagnostic agents, and the like. In one embodiment, the linker attaches a Biologically Active Molecule and a Ligand. In another embodiment, the linker attaches a biologically active macrolide and a Ligand. In yet another embodiment, the linker attaches a biologically active macrolide and an antibody or fragments thereof.
[0058] In one aspect, the linkers are useful to covalently link ligands with therapeutic agents and markers. In another aspect, the linkers improve chemical and/or systemic stability of the attached moieties. In another aspect, the linkers reduce in vivo toxicity of the attached moieties. In another aspect, the linkers improve pharmacokinetics, pharmacodynamics, and/or bioavailability of the attached moieties. In one aspect, the linkers cleave and release a Biologically Active Molecule at a site in or near a target ceil or a cell population in a pharmacologically effective form. In one aspect, the cleavage is performed by enzymes. In one aspect, the cleavable groups on the linkers for the enzymatic cleavage include, but not limited to, peptide bonds, ester linkages, and disulfide linkages. In another aspect, the linker is cleaved through pH changes.
[0059] In one embodiment, the linker compounds is represented by formula (VI):
Z2 A— W— X Y Zl (VI)
wherein:
Zz and Z1 are each independently absent or a spacer;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CRs¾-, -N¾
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted; Y is absent,
Figure imgf000015_0001
or
Figure imgf000015_0002
wherein Als A3, Ri and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an aikynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5Rs-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0, -0-C(=0)-0-, -C(=0 (CHx)pl-,
Figure imgf000015_0003
-(0-(CH2)p2-)p3-! - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, - R4-, -N(R})-C(=0)-N(Rs)-, -N(R4 C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4)-, -C(=0)- N(R4)-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, aikynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRig-, -CR5R6-;
Ri7 is selected from the group consisting of O, S, NRig, CR5¾;
Ri8 is selected from the group consisting of H, alkyl, aikynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, aikynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, Rs, R¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, aikynyl, aryl, heteroaryl, or heterocyclyl;
pi , p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
[0060] In one aspect, the disclosure provides compounds of formula (VI), wherein Z2 is represented by the following structural formula:
Figure imgf000015_0004
wherein:
¾A, ¾B, ¾c an^ Z2D re eacn independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an aikynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5¾-, -0-, -C(=0)-, -0-C(=0)-, -C(=0 0-, -OC(=0)-0-, -C(=0)-(CHx)pl, -C(=0)-0-(C¾)Pi, -(C¾)pl-C(=0)-, -(CHx)pl-C(=0)-O, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-,■ C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S , -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N( |)- C(=0)-N(Rs)-, -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -0(Ο)-Ν(¾)-, -C(=0)-N(R4)-C(=0 , -O-
Figure imgf000016_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Rfi and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0061] In one aspect, the disclosure provides compounds of formula (VI), wherein Zi is represented by the following structural formula:
Figure imgf000016_0002
wherein:
iA, iB, Zic and Z\B are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5Ri-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(C¾)pi, -C(=0)-0-(CHx)pl, -(CHx)pl-C(=0)-, -(C¾)pi-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, - C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S , -S-C(=S)-S-, -S-, -SO-, -S02-, - ¾-( -N(R4)- 0(=Ο Ν(¾ . -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0 N(R4 , C(=0)-N(R4)-C(=0)-, -O-
Figure imgf000016_0003
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, Rs, and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0062] In one aspect, the disclosure provides compounds of formula (VI), wherein A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
[0063] In another one aspect, the disclosure provides compounds of formula (VI), wherein A is a peptide selected from the group consisting of valine-citruiline, citrulline- valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, serine- asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine.
[0064] In one aspect, the disclosure provides compounds of formula (VI), wherein X is an aryl
Figure imgf000017_0001
wherein ¾, Rio, Rn, and R are each independently H, an alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, NR13R14, nitro, cyano, -OH, -0-C(=0)-R]5, -C(=0)-Ri5, -
Figure imgf000017_0002
further wherein, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Rn and H are each independently H or an optionally substituted alkyl; and R s is an optionally substituted alkyl.
[0065] According to certain embodiments, the linkers, the biologically active molecules, and other compounds of the present disclosure can be connected to an antibody or antigen-binding molecule through an attachment at a particular amino acid within the antibody or antigen-binding molecule. Exemplary amino acid attachments that can be used in the context of the disclosure include, e.g., lysine (see, e.g., US 5,208,020; US 2010/0129314; Hollander et al., Bioconjugate Chem,, 2008, 19:358-361; WO 2005/089808; US 5,714,586; US 2013/0101546; and US 2012/0585592), cysteine (see, e.g., US 2007/0258987; WO 2013/055993; WO 2013/055990; WO 2013/053873; WO 2013/053872; WO 2011/130598; US 2013/0101546; and US 7,750,116), selenocysteine (see, e.g., WO 2008/122039; and Hofer et al., Proc. Natl. Acad. Set., USA, 2008, 705:12451-12456), formyl glycine (see, e.g., Carrico et al, Nat. Chem. Biol, 2007, 3:321-322; Agarwal et al, Proc. Natl. Acad. Set, USA, 2013, 110:46-51, and Rabuka et al, Nat. Protocols, 2012, 70: 1052-1067), non-natural amino acids (see, e.g., WO 2013/068874, and WO 2012/166559), and acidic amino acids (see, e.g., WO 2012/05982). Linkers can also be conjugated to an antigen-binding protein via attachment to carbohydrates (see, e.g., US 2008/0305497, and Ryan et al., Food &
Agriculture Immunol, 2001, 73:127-130) and disulfide linkers (see, e.g., WO 2013/085925, WO 2010/010324, WO 201 1/018611, and Shaunak et al., Nat. Chem. Biol, 2006, 2:312- 313).
[0066] According to certain other embodiments, the linkers, the biologically active molecules such as drugs can be connected to an antibody or antigen-binding molecule through an attachment at a particular amino acid within the antibody or antigen-binding molecule forming an antibody-drug conjugate (ADC).
Compounds
[0067] In one aspect, the present disclosure provides Biologically Active Molecules and Ligand conjugates represented by the following structural formula (I):
Figure imgf000018_0001
wherein:
L is absent or a Ligand;
further wherein:
when L is a Ligand, L is capable of binding to a cell or cell populati on;
a is an integer from 1 to 10;
∑2 and Z] are each independently absent or a spacer;
D is a Biologically Active Molecule;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R6-, - R4-;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted; Y is absent,
Figure imgf000019_0001
, or
Figure imgf000019_0002
wherein Ai, A3, Ri and R3 are each inde endently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-s -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)- (CHx)pl-,
Figure imgf000019_0003
-(0-(CH2)p2-)p3-, - ((CH2)p2-0-)P3-, -C(=S)-S -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, - NR4-, -N(R4)-C(=0)-N(R8)-, -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4)-, -C(=0)- N(R4)-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRig-, -CR5R6-;
Ri7 is selected from the group consisting of O, S, N is, CRsRg;
Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, R5, R6 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
[0068] In another aspect, the present disclosure relates to compounds where the Biologically Active Molecule is a cytotoxic biologically active macrolide.
[0069] In yet another aspect, the present disclosure provides maytansinoids as represented by formula (II) as biologically active macrolides:
Figure imgf000020_0001
wherein AG, A7, AS, Ag are each independently absent, an amino acid, N-alkyl amino acid, a peptide having 2-20 amino acids, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0 , -0-C(=0 , -C(=0)-0-, -0-C(=0)-
Figure imgf000020_0002
)p3-, -((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-NH-, -C(=S)-S-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -
Figure imgf000020_0003
C(=0)-N(R4)-C(=0 , -0-C(=0)-NR4, further wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted; and R4, R5, Re and Rs are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0070] In another embodiment, the maytansinoid is represented by the following structural formula (II)(a):
Figure imgf000020_0004
[0071] In one aspect, the disclosure provides a compound of formula (I), wherein the
Ligand (L) is capable of binding to a specifically targeted cell population.
[0072] In another aspect, the disclosure provides a compound of formula (I), wherein the Ligand (L) is selected from the group consisting of proteins, antibodies, fragments of antibodies, nucleic acids, antigen binding scaffolds, and carbohydrates.
[0073] In one embodiment, the disclosure provides a compound of formula (1), wherein the Ligand (L) is an antibody or a fragment thereof. [0074] In one embodiment, the disclosure provides a compound of formul a (I), wherein Ligand (L) is an antibody or fragment thereof that specifically binds a tumor associated antigen,
[0075] In one embodiment, the disclosure provides a compound of formula (I), wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with Z2.
[0076] In one aspect, the disclosure provides compounds of formula (I), wherein Z2 is represented by the following structural formula:
-Z2A-Z2B -Z2C-Z2D-,
wherein:
Z A, ZTB, Z2C and Z2D are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pi, -C(=0)-0-(CHx)pb -(CHx)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)P2-)P3-, -((CH2)P2-0-)P3-, - C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S>S-, -S-, -SO-, -S<¾-, -NR4-, -N(R4 - =0)0-, -N(R4)-C(=0)-, -C(=0)-N( )-, -C(=0)-N(R4)-C(=0)-, -O-
Figure imgf000021_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0077] In one embodiment, the disclosure provides compounds of formula (I), wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with 2Α·
[0078] In one aspect, the disclosure provides compounds of formula (I), wherein Zi is represented by the following structural formula:
- 1 A- 1B- 1C- 1D-,
wherein: ZiA, ZiB, Zic and ZJD are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyi, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0 , -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pl, -C(=0 0(CHx)pl, -(CHx)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0(CH2)P2-)P3-, -((CH2)P2-0-)p3-, - C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(Rt> C(=0)-N(Rs)-, -N(R4)-C(=0)0-, -N(R4 C(=0)-, -C(=0)-N(R4)-, C(=0)-N(R4)-C(=0 , -O-
Figure imgf000022_0001
wherein alkyl, alkynyl, alkenyi, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R , R5, Rg and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyi, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0079] In one embodiment, the disclosure provides compounds of formula (I), wherein the Biologically Active Molecule (D) is covalently attached with Z\,
[0080] In one aspect, the disclosure provides compounds of formula (1), wherein A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citrulline.
[0081] In another aspect, the disclosure provides compounds of formula (I), wherein A is a peptide selected from the group consisting of valine-citrulline, citrulline-valme, lysine- phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine- asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine- phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine- isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine- glutamic acid, citruiline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine- alanine.
[0082] In one aspect, the disclosure provides compounds of formula (I), wherein X is an aryl selected from the group consisting of
Figure imgf000023_0001
wherein R¾ Rio, Rn, and Rn are each independently H, an alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, N 13R14, nitro, cyano, -OH, -0-C(=0)-Ri5, -C(=0)-Ri5, - C(=0)-0-R, 5, -C(=0)-NR13 R] ; and
further wherein, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri3 and R14 are each independently H or an optionally substituted alkyl; and 15 is an optionally substituted alkyl.
[0083] la (III):
wherein:
Ab is an antibody or a fragment thereof;
AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine- asparagine, asparagine-pheny 1 alanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5; A3, ] and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-,
Figure imgf000024_0001
-C(=0)-0-(C¾)pl-, -(CHx)pl-C(=0>, -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, - R4-, -Ν(¾)- C(=0)-N(Rg)-, -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -0(=Ο)-Ν(¾)-, -C(=0)-N(R4 C(=0 3 -O- C(=0)-NR-i-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri7 is selected from the group consisting of O, S, NRig, CR5R6;
Ri, R5, ¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
R9, Rio, Ri i, and R!2 are each independently H, halogen, NR13R14, nitro, cyano, -OH, -
Figure imgf000024_0002
Rw, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
Ri3 and H are each independently H or an optionally substituted alkyl; and Ru is an optionally substituted alkyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and DM is represented by the following structure (e.g., compound of formula
Figure imgf000024_0003
[0084] In one embodiment, the disclosure provides the compounds of formula (ill) wherein:
q is 4;
Rj and R3 are each independently -0-, -S-, R4, -CR5R6-;
R] is selected from the group consisting of O, S, NR]g, CRsRg;
Ri8 is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted; R4, R^ R^ Rp, io, Ri i, R12 are each independently H or alkyl; and
A3 is an alkyl.
[0085] In one embodiment, the disclosure provides the compounds of formula (III) represented
Figure imgf000025_0001
(III)(a) and
(III)(b) wherein Ab is an antibody or a fragment thereof.
[0086] In one aspect, the disclosure provides the compounds of formula (IV):
Figure imgf000025_0002
wherein:
Ab is an antibody or a fragment thereof;
is a peptide selected from the group consisting of valine-citrulline, citrulline- valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine- sparagine, asparagine- leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine; a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5;
R( is absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -O- C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)p,-, -C(=0)-0-(CHx)p , -(CHx)pl-C(=0)-, - (CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-
Figure imgf000026_0001
- N(R4)-C(=0)-,
Figure imgf000026_0002
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
4, is H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
R9, Rio, R11, and j2 are each independently H, halogen, NR13R14, nitro, cyano, -OH, -
Figure imgf000026_0003
Ru, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
llowing structure:
Figure imgf000026_0004
(DM).
[0087] embodiment, the disclosure provides the compounds of formula (IV) wherein:
q is 4; and
R] is selected from the group consisting of-O-, -S-, NR4, and -CR5R5-; and further wherein R4, R5j and Re are each independently H or alkyl.
[0088] In one embodiment, the disclosure provides the compounds of formula (IV) represented by the following structure (IV)(a):
Figure imgf000027_0001
wherein Ab is an antibody or a fragment thereof.
[0089] in one aspect, the disclosure provides a compound of Formula (V)
Z2 A— W— X Y Z,— D (V)
wherein:
Z2 and Zi are each independently absent or a spacer;
D is a Biologically Active Molecule;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino W is absent, -0-, -S-, -CR5R-6-, or -NR4S
X is absent, or a substituted or unsubstituted: aryl, heteroaryl, cycloalkyl, hetero
Figure imgf000027_0002
wherein Ai, A3, Ri and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)- (C¾)pr, -C(=0)-0-(CHx)pl-, -(CHs)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)p2-0)p3-, -C(=S>, -C(=S)-S-, -C(=S)-NH~, -S-C(=S>, -S-C(=S)-S-, -S-, -SO-, -S02-, - R4-, -N(R4)-C(=0)-N(Rg)-5 -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4>, -C(=0)- N(R-4)-C(=0)-, -0-C(=0)- R4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryi, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRig-, -CRjRe
Ri7 is selected from the group consisting of O, S, NRis, CRsRe;
RIB is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
Rt, R5, Re and ¾ are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
pi , p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
[0090] In one embodiment, the disclosure provides the compound of formula (V), wherein:
Z2 is represented by Formula (VII):
-¾A-¾B-¾C-Z2D- (VI 1),
further wherein:
Z2A, Z2B, Z2c and Z2D are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0 , -C(=0)-0-, -OC(O)-0-, -C(=0)-(CHx)pl, -C(=0)-0-(CHx)pl, -(C¾)pl-C(=0)-, -(CHx)pI-C(=0)-0-, -(0-(CH2)P2-)P3-, -((C¾)p2-0-)p3-, - C(=S)-} -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(EL,)- =0)-N(R8)-, -N(R4)-C(=O)0-, -N(R4)-C(=0 , -CC=0)-N(E )-} -C(=0)-N(R4)-C(=0)-, -O-
or
Figure imgf000028_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, e and R8 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
Zi is represented by Formula (Vlli): -ZjA- lB-Zic-ZiEr (VIII),
wherein:
IA> iB, ic and m are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5¾-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pi,
Figure imgf000029_0001
-(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, - C(=S>, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -SO , -NR4-, -N(R4> =0)-N(Rg)-, -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4)-, -C( ))-N(R -C(=O)-, -O-
Figure imgf000029_0002
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, R , ¾ are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
A is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine- asparagine, serine-asparagine, asparagine- serine, phenyl alanine-asparagine, asparagine- phenylalanine, leucine-asparagtne, asparagine-leucine, isoleucine-asparagine, asparagine- isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine- glutamic acid, citrulline-asparagme, asparagine-citrulline, alanine-asparagine, asparagine- alanine; and
Figure imgf000029_0003
wherein R?, Rio, Rn, and Rj2 are each independently H, an alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, NR13R14, nitro, cyano, -OH, -0-C(=0)-Ri5, -C(=0)-R]5, -
Figure imgf000029_0004
further wherein, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri3 and RH are each independently H or an optionally substituted alkyl; and R] 5 is an optionally substituted alkyl. [0091] The Biologically Active Molecules (D) can optionally be a substituted maytan
Figure imgf000030_0001
wherein:
As, A7, As, A9 are each independently absent, an amino acid, N-alkyl amino acid, a peptide having 2-20 amino acids, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0>, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, - C(=0)-(CHx)pi, -C(=0)-0-(C¾)pl, -(C¾)p!-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S , -S-C(=S)-S-, -S-, -SO-, -SOz-, - NR4-, -N(R4)-C(=0)-N(R8)-, -N(R4 C(=0)0-, -N(R4 C(==0)-, -C(=0)-N(R4>, C(=0)- N(R4)-C(=0)-, 0-C(=0)-NR4, further wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and R4, R5, R¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl.
[0092] In another embodiment, the disclosure provides compounds of formula (V), wherein the biologically active molecule is a optionally substituted maytansinoid represented by the
Figure imgf000030_0002
wherein:
Aa, A7, Ag, Ag are each independently absent, an amino acid, N-alkyi amino acid, a peptide having 2-20 amino acids, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=O)-0-, -0-C(=0)-0-, - C(=0)-(CHx)pl, -C(=0)-0-(CHx)p l, -(CHx)pl-C(=Oh -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)P2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S<¼-, - NR4-, -N(R4)-C(=0)-N(Rs)-, -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R )-, C(=0)- N(R4)-C(=0)-5 0-C(=0)-NR4, further wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and R4, R5, Rs and Rg are each independently H, or a substituted or unsubstiiuted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl.
[0093] In yet another embodiment, the disclosure provides compounds of formula (V), wherein the biologically active molecule is a maytansinoid represented by the following structural formula:
Figure imgf000031_0001
(DM).
[0094] In one embodiment, the disclosure provides compounds of formula (V) represe (V)(d), and (V)(e):
Figure imgf000031_0002
[0095] In one aspect, the disclosure provides the compounds of formula (IX):
Y, Z— (IX)
wherein:
D is a Biologically Active Molecule;
Figure imgf000032_0002
wherein R.3a and A3a are each independently absent, an amino acid, a peptide having 2-20amino acids, an alkyl, an alkynyl, an alkenyl, a cycioalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R;-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pi-, -C(=0)-0-(CHx)pr, -(CHx)pl-C(=0)-, -(CHs)p,-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -SO2-, -NR4-, -N(Ri)- C(=0)-N(R8)-, -N(R4)-C(=0)O, -N(R4)-C(=0)-, -C(=0)-N(Rt)-s -C(=0)-N(R4)-C(=0)-, -O- C(=0)-NRi-3 wherein alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted; and
Zi is represented by following structural formula:
-Zi A-Z 1B-Z 1 c-ZiD",
wherein:
ZiA, iB, Zic and ZiD are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycioalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0 , -0-C(=0>, -C(=0 0-, -0-C(=0)-0-, -C(=0)-(CHx)pi, -C(=0>0-(CHx)pl, -(C_¾pi-C(=0)-, -(CHx)p,-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-,■ C(=S)-S -C(=S)-S-, -C(=S)- H-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -N 4-, -N(R4> =0)-N(R8)-, -N(R4)-C(=0)0-, -N(R4)-C(=0 , -C(=0)-N(R >, C(=0)-N(R4>C(=0>, -O-
Figure imgf000033_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, ¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
[0096] In another aspect, the disclosure provides compound of formula (IX) wherein the Biologically Active Molecule is a cytotoxic biologically active macrolide. In yet another aspect, the disclosure provides compound of formula (IX) wherein the biologically active macrolide is a maytansinoid. In a further aspect, the disclosure provides compound of formula (IX) wherein the maytansinoid is represented by formula (II). In another aspect, the disclosure provides compound of formula (IX) wherein the maytansinoid is represented by formula (II)(a).
[0097] In an aspect, the disclosure provides a compound of formula (IX) wherein IC50 of the compound is greater than about 10 nM.
[0098] In an aspect, the disclosure provides a compound of formula (IX) wherein the compound is about 10 fold less cytotoxic than the corresponding compound of formula (I).
[0099] In another one aspect, the disclosure provides compounds of formula (X):
Figure imgf000033_0002
wherein:
Ab is an antibody or a fragment thereof;
a is an integer from 1 to 10;
Z2 and Zi are each independently absent or a spacer; A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R0-, -NR4-;
X is absent, aryl, heteroaryl, cycioalkyl, heterocyclyl, wherein aryl, heteroaryl, cycio
Figure imgf000034_0001
wherein A1} A3, i and 3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycioalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)- (CH p , -C(=0)-0-(CHx)p,-, -(C¾)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, - NR4-, -N(R4)-C(=0)-N(Rs)-, -N(R4)-C(=0)0-, -N( 4)-C(=0 , -C(=0)-N(R4)-, -C(=0>
Figure imgf000034_0002
-0-C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRig-, -CR5R6-;
Ri7 is selected from the group consisting of O, S, NRig, C 5¾;
ig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycioalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
pi , p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and
DM is represented by the following structure:
Figure imgf000035_0001
[00100] In one embodiment, the disclosure provides the compound of formula (X) represented by the following structure (X)(a):
Figure imgf000035_0002
wherein a is an integer from 1 to 10.
[00101] In another aspect, the disclosure provides the compound of formula (XI):
Figure imgf000035_0003
wherein:
Ab is an antibody or a fragment thereof;
AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulHne-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparaguie, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citralline, alanine-asparagine, asparagine-alanine;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5; A3, Ri and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)Pi-, -C(=0)-0-(CHx)pl-, -(CHx)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, -((CH2)p O-)p3-, -C(=S>, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(R,)-
Figure imgf000036_0001
C(=0)-NR4~, wherein alkyl, alkynyl, alkenyl, cycloailtyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri7 is selected from the group consisting of O, S, NRis, CR5R6;
R4, R5, ¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryi, heteroaryl, and heterocyclyl;
R9, Rio, R11, and Ri2 are each independently H, halogen, NR13R14, nitro, cyano, -OH, - 0-C(=0)-Ri5, -C(=0)-R,5, -C(=0)-0-R15, -C(=0)- R13 RH, substituted or unsubstituted: alky], cycloalkyl, aryl, heteroaryl, and heterocyclyl;
Ri3 and RH are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and
llowing structure:
Figure imgf000036_0002
[00102] In one embodiment, the disclosure provides the compound of formula (XI) represented by the following structure (XI)(a):
Figure imgf000036_0003
(XI)(a) wherein a is an integer from 1 to 10.
[00103] In one aspect, the disclosure provides the compounds of formula (I), (III), (IV) (V), and (X), wherein A is a peptide cleavable by a protease.
[00104] In one aspect, the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease.
[00105] In one aspect, the disclosure provides the compounds of formula (1), (III), (IV) (V), and (X) wherein A is a peptide cleavable by a protease expressed in tumor tissue.
[00106] In one aspect, the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease expressed in tumor tissue.
[00107] In an embodiment, the disclosure provides the compounds of formula (I), (III),
(IV) (V), (X) wherein A is a peptide cleavable by a protease further wherein the protease is a cathepsin or a plasmin.
[00108] In an embodiment, the disclosure provides the compound of formula (XI) wherein the peptide is cleavable by a protease further wherein the protease is a cathepsin or a plasmin.
Compositions
[00109] Embodiments herein include compositions comprising conjugate compounds of formul (I), (III), (IV), (V), (X), or (XI) as well as mixtures thereof. In some aspects the compound is further represented by a compound of formula (III)(a), (III)(b), (IV)(a), (V)(a),
(V) (b), (V)(c), (V)(d) (V)(e), (X)(a), or (XI)(a).
[00110] Embodiments herein include compositions comprising compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) as well as mixtures thereof.
[00111] Compositions may be pharmaceutical compositions that further include one or more pharmaceutically acceptable carriers, diluents, and/or excipients. In some aspects the pharmaceutical composition is the pharmaceutically acceptable salt of compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) or mixtures thereof. In some other aspects the pharmaceutical composition is the pharmaceutically acceptable salt of compounds of formula (I), (III), (IV), (V), (IX), (X), or (XI) or mixtures thereof.
[00112] Suitable pharmaceutical acceptable carriers, diluents and excipients are well known in the art and can be determined by one of ordinary skill in the art as the clinical situation warrants. Examples of suitable carriers, diluents and excipients include: buffers for maintenance of proper composition pH (e.g., citrate buffers, succinate buffers, acetate buffers, phosphate buffers, lactate buffers, oxalate buffers and the like), carrier proteins (e.g., human serum albumin), saline, polyols (e.g., trehalose, sucrose, xylitol, sorbitol, and the like), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxolate, and the like), antimicrobials, and antioxidants.
[00113] If so desired, the pharmaceutical compositions herein may include a second or more therapeutic agent (e.g., an adjuvant to the conjugate compounds of formula (I), (III),
(IV) , (X), and/or (XI), anti-tumor agents, antibiotics, anti-inflammatories, and the like). The second therapeutic agent can be included in the same composition as the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI), or can be administered separately from the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) (by time, or type and location of administration).
[00114] One of skill in the art of Biologically Active Molecules will understand that each of the compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) can be modified in such a manner that the resulting compound still retains specificity and/or activity similar to the starting compound. In this light, the Biologically Active Molecule (D) of compounds of formula (I), (III), (IV), (V), (IX), (X), and/or (XI) can include any and all of the Biologically Active Molecules' analogues and derivatives. In one embodiment the Biologically Active Molecules is a macrolide and further is maytansine or an analogue of maytansine as described in Widdison et al, J. Med. Chem., 2006, 49 (14), 4392-4408.
[00115] In one aspect, the disclosure provides the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) , (III) ,(IV), (X), (XI) including (IIl)(a), (III)(b) (lV)(a), (X)(a), and (XI)(a), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[00116] In one aspect, the disclosure provides the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) , (III) ,(IV), (V),
(IX) , (X), (XI) including (III)(a), (III)(b) (IV)(a), (V)(a), (V)(b), (V)(c), (V)(d), and (V)(e),
(X) (a), and (XI)(a), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[00117] In another aspect, the disclosure provides pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (V) including
(V) (a), (V)(b), (V)(c), (V)(d), and (V)(e), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients. [00118] In another aspect, the disclosure provides pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (IX), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[00119] In another aspect, the disclosure provides pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (V) and (ΪΧ) including (V)(a), (V)(b), (V)(c), (V)(d), and (V)(e), or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
Method of Use
[00120] As described above, conjugate compounds of formula (I), (III), (IV), (X), and (XI) can be produced with various functional groups such that attachment of the Ligand (L) to the linker and thereby a Biologically Active Molecule form a covalent conjugate. The Ligand specially targets the conjugate compound to the Ligand binding partner, typically a polypeptide or other like antigen. In typical embodiment, the conjugate is designed to include a Ligand having a binding partner found on cells undergoing abnormal cell growth or cells involved in a proliferative disorder. Surprisingly, conjugate compounds of formula (I), (III), (IV), (X), and (XI) have been designed such that each compound's linker is catabolized inside the cell bound by the conjugate. As such, delivery of a Biologically Active Molecule through the conjugate embodiments herein allows for delivery of Biologically Active Molecules that would normally be too toxic to administer conventionally. The embodiments herein allow for highly selective and specific delivery of these molecules to cells undergoing abnormal cell growth or cells involved in proliferative disorders (as compared to catabolism outside the cell, thereby releasing the biologically active compound into the blood or lymphatic system, for example).
[00121] As can be envisioned by one of skill in the art, the covalent conjugate compounds described herein can also be used to deliver any type of useful Biologically Active Molecule and can be selectively targeted to any type of cell population, for example, the conjugate may be used to deliver anti-proliferative drugs to cells undergoing abnormal growth or anti-viral drugs to cells infected with a virus, as long as the selected Ligand recognizes a proper cell binding partner.
[00122] In this light, methods of use are provided for the conjugate compound embodiments described herein. [00123] The pharmaceutical compositions described herein are useful in inhibiting, retarding and/or preventing abnormal cell growth or in the treatment of various proliferative disorders or disease states in mammals. In typical embodiments the mammal is a human (embodiments herein will be described in relation to humans). Other mammals include any mammal that can suffer from a detectable proliferative disorder, including primates, dogs, cats, horses, goats, sheep, cattle, camels, and the like. In addition, it is understood that the conjugate compounds of the pharmaceutical compositions are designed for selective targeting to the cells undergoing abnormal cell growth or for the treatment of the various proliferative disorders or disease states described herein.
[00124] As such, embodiments herein include methods of inhibiting abnormal cell growth or treatment of a proliferative disorder in a human comprising administering to the human a therapeutically effective amount of a pharmaceutical composition described herein.
[00125] Administration of a therapeutically effective amount of a pharmaceutical composition described herein may be effected in different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal, or
intrabronchial administration. The pharmaceutical compositions herein may also be administered directly to an abnormal cell growth site (directly or indirectly contacting the abnormal cell growth) by, for example, biolistic delivery (biolistic delivery of the pharmaceutical compositions herein to a lung or brain tumor, for example). Dosage regiments for administration of the pharmaceutical compositions herein will be determined by the attending health care professional or other person of skill in the art as well as based on the particular clinical situation. As is well known in the pharmaceutical arts, dosages for any one human, i.e., patient, depends on a number of factors, including patient size, patient's body surface area, patient's age and general health, patient's sex, the time and route of administration, and presence of a second therapeutic agent. In some instances the conjugate compounds of formula (I), (III), (IV), (X), and/or (XI) may be present in amounts between 1 μg and 100 mg/kg body weight per dose (note that where continuous infusion is considered as an administration route, as little as 1 pg/kg body weight per minute may be considered). Pharmaceutical compositions can be administered one or more times a day and over a period of days, weeks, months, or years.
[00126] Treatment of proliferative disorder or disease, for example a tumor, includes methods of reducing a tumor size, causing necrosis or apoptosis in a tumor, killing a tumor, stopping a tumor from increasing in size and/or preventing invasiveness or metastasis of a tumor.
[00127] Examples of medical conditions that can be treated according to methods of inhibiting abnormal cell growth, or treating proliferative disorders include: malignancy of any type, e.g., cancer of the lung, colon, prostate, kidney, pancreas, liver, ovary, skin, lymphoma, leukemia and the like; autoimmune diseases, e.g., systemic lupus, rheumatoid arthritis, multiple sclerosis; viral infections, e.g., CMV infection, HIV infection, AIDS, Hepatitis, HPV infection; pain; mental disorders; and inflammatory diseases.
[00128] As noted above, pharmaceutical compositions described herein are also useful in the prevention or treatment of viral infections, pain, inflammatory diseases, autoimmune diseases, and the like in a mammal.
[00129] In one aspect, the disclosure provides a method of reducing, retarding or stopping an abnormal cell growth comprising contacting the abnormal cell with a compound of formula (I), (III) (IV), (X), and/or (XI) in an amount sufficient to retard, reduce or stop the abnormal cell growth, and wherein the abnormal cell growth is retarded, reduced or stopped.
[00130] In one aspect, the disclosure provides a method of killing a cell, comprising contacting the cell with a compound of formula (I), (III), (IV), (X), and/or (XI) in an amount sufficient to kill the cell, and wherein the cell is killed.
[Θ0131] In one embodiment, the disclosure provides a method of killing a cell, comprising contacting the cell with a compound of formula (I), (III), (IV), (X), and/or (XI) in an amount sufficient to kill the cell, and wherein the cell is killed and further wherein the cell is a tumor cell.
[00132] In one aspect, the disclosure provides a method of treatment of a medical disorder in an indi idual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI).
[00133] In one other aspect, the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (V), (IX), (X), and/or (XI).
[00134] In one embodiment, the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy.
[00135] In one embodiment, the disclosure provides methods, wherein additional therapy is radiation therapy, chemotherapy, or a combination of both.
[00136] In one embodiment, the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy and administering at least one additional therapeutic agent.
[00137] In one embodiment, the disclosure provides a method of treatment of a medical disorder in an individual suffering from the medical disorder comprising administering to the individual an effective amount of a composition comprising a compound of formula (I), (III), (IV), (X), and/or (XI) and further comprising administering sequentially or consecutively an additional therapy or administering at least one additional therapeutic agent.
[00138] In one aspect, the medical disorder treated is selected from tumors, cancers, infectious diseases, neurodegenerative diseases, bone disorders, and cardiovascular diseases.
[00139] Embodiments herein also provide methods of preparing compounds of formula (I) from precursor or building block compounds of formula (V). In some aspects the compounds of formula (V) can also be used in therapeutic application where the compound of formula (V) is a pharmaceutical composition. In some aspects compounds of formula (V) can be included in any of the compositions or pharmaceutical compositions of compound (I), (III), (IV), (IX), (X), and/or (XI).
[00140] Finally, embodiments herein may include mixtures of compounds as represented by formula (I), (III), (IV), (V), (IX), (X), and/or (XI).
Production of Conjugates
[00141] The Ligand-Biologically Active Molecule conjugate compounds can be generated by any technique known to the skilled artisan. The Ligand-Biologically Active Molecule conjugate compounds comprise a Ligand unit, a Biologically Active Molecule, and optionally a Linker that joins the Biologically Active Molecule and the Ligand. The covalent attachment of Biologically Active Molecules and/or Linkers to the Ligand can be accomplished using variety of reactions using the amino acid residues of the Ligand, e.g., antibody, including the amine groups of lysine, the free carboxylic acid groups of glutamic and aspartic acid, the sulfhydryl groups of cysteine and the various moieties of the aromatic amino acids.
[00142] Further, conjugates in accordance with various embodiments described herein can be prepared by any known method in the art. An illustrative protocol for producing conjugates is provided in the Examples below. However, other known methods can be used, including, for example, protocols described in WO 2009/134977, US Patent No. 7,81 ,572 and US Patent No. 6,441,163, as long as the protocols are used to prepare the compounds as described herein. These references are incorporated by reference for their intended purpose.
[00143] In one embodiment, the conjugates can be prepared by i) reacting a Ligand with Linker to form a modified Ligand-Linker compound; ii) optionally purifying the Ligand- Linker compound; iii) conjugating a Biologically Active Molecule, e.g., a macrolide, to the Ligand-Linker to form a conjugate of formula (I), (III), (IV), (X), or (XI); and iv) purifying the conjugate.
[Θ0144] In an alternative embodiment, the conjugates can be prepared by reacting a Biologically Active Molecule with a first component of the Linker (Zi), followed by successive reactions to build out the Linker, including addition of Y, X, W, A and Z2, or any combination thereof.
[00145] In an alternative embodiment, the conjugates are prepared by reacting a Ligand, Linker and biologically active macrolide in a single reaction. Once the conjugates in accordance with the invention are prepared they can be purified.
Identifying Cytotoxicity of Conjugate Compounds
[00146] In one embodiment, the conjugate compounds described herein can be evaluated for their ability to suppress proliferation of various cancer cell lines in vitro. The in vitro cytotoxicity assays can be conducted using methods known in the art (see Widdison et al., J. Med. Chem., 2006, 49(14), 4392-408) and as illustrated in Example 7 herein. For example, conjugate compounds can be applied to in vitro plated cancer cells for a predetermined number of days and surviving cells measured in assays by known methods. Proper controls can be utilized to ensure validity of results as can IC50 values. Examples of in vitro potency of conjugate compounds herein can be seen in Figures 1 and 2. Additional in vivo efficacy can be used to confirm proposed conjugate compound potency - for example using a nude mouse model. [00147] The above specification, examples and data provide a complete description of the manufacture and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended.
[00148] All references cited herein and in the Examples that follow are expressly incorporated by reference in their entireties.
[00149] The description and Examples presented infra are provided to illustrate the subject invention. One of skill in the art will recognize these Examples are provided by way of illustration only and are not included for the purpose of limiting the invention.
EXAMPLES
Experimental Details
[00150] Proton NMR spectra (for compounds that could not be detected by UV) were acquired on a Varian Inova 300 MHz instrument, while mass spectra were collected on an Agilent 1100 series LC/MSD with electrospray ionization source and triple-quad ion trap analyzer. Appropriate conjugates were analyzed using a Bruker ultraFleXtreme MALDI- TOF-TOF mass spectrometer. All starting materials and solvents were purchased commercially and used without purification, unless otherwise noted.
EXAMPLE 1
[00151] Step 1 : Maytansin-3 -N-m ethyl-L~ lan ine (2)
[00152] The title compound was prepared as a gold solid from maytansinol (1) using the methods described in U.S. Patent Application 2007/0037972 AL MS (ESI, pos.): calc'd for C32H44CIN3O9, 649.3; found 650.6 (M+H).
[00153] Step 2: Maytansin-3-N-methyl-L-(S) ~alanine-N-[ 4- (amino-citrulline-valine- hexanam ide-6-maleim idyl) benzyl] carbarn ate (3):
[00154] The product of the preceding step (2, 0.020 g, 0.031 mmol) and p-N02-Ph- carbonato-Bn-Cit-Val-maleimide (MA-VC-PAB-PNP, 0.027 g, 0.037 mmol; Concortis Biosystems) were dissolved in Ν,Ν-dimethylformamide (DMF, ca. 0.25 mL) in a conical vial, treated with Brockmann I basic alumina (0.10 g), the vial purged with argon, and the reaction stirred at ambient temperature for 4 days. The mixture was then filtered, the solids washed with acetonitrile/water, and filtrate purified directly on a 5u, 30x150 mm Phenomenex Gemini C18 column via HPLC (30 - 90% acetonitrile in water, 0.1% TFA in both, over 25 min, 15 mL/min). Lyophilization of the purest fractions overnight gave the title compound as a pale yellow solid (0.021 g, 55%). MS (ESI, pos.): calc'd for C61H82CIN9O17, 1247.6; found 1248.8 (M+H), 1270.7 (M+Na), 1231.5 (M-H20+H).
Figure imgf000045_0001
3
EXAMPLE 2
[00155] Step 1: N-tert-Butoxycarbonyl-beta-alanine succinate ester (4)
[00156] The title compound was prepared from commercial Boc- -alanine by a method well known in the art {c.f.- Widdison et al., J. Med. Chem., 2006, 49 (14), 4401). 'H NMR
(300 MHz, CDCI3): δ 3.62 (bm, 2H), 2.88 (m, 9H), 1.47 (s, 9H).
[00157] Step 2: Mayt nsin-3-N-methyl-L-(S)-alanine-Boc-fi-Ala (5)
[00158] The product of the preceding step (4, 0.45 g, 1.51 mmol) and maytansin-3-N- methyl-L- lanine (2, 0.30 g, 0.23 mmol) were dissolved in 3:1 acetonitrile: water (8 mL), treated with 1M aqueous NaHC(¾ (0.5 mL), and stirred at ambient temperature for 18h.
When the reaction was complete by TLC, it was then stirred with brine for 10 min and extracted thrice with ethyl acetate (EtOAc). The combined organic layers were then dried over Na2S0 , filtered, and the filtrate concentrated and dried in vacuo to a gold syrup that was purified by flash column chromatography on a 20g silica gel cartridge (0 - 10% MeOH in EtOAc over 15 min) giving the title compound as a white solid (0.084 g, 43%). MS (ESI, pos.): calc'd for C41H59CIN4O12, 834.4; found 835.2 (M+H), 857.2 (M+Na), 817.4 (M-
H20+H). [00159] Step 3: Maytansm-3-N-jnethyl-L-(S)-alanine-fi-Ala (6)
[00160] The product of the preceding step (5, 0.080 g, 0.095 mmol) was dissolved in a 3: 1 : 1 mixture of acetonitrile/water/trifluoroacetic acid (4 mL) and stirred at ambient temperature for 26 hours. The crude reaction mixture was injected directly onto a 40g C18 silica gel column and eluted via ISCO CombiFlash (10 - 90% acetonitrile in water, 0.1 % TFA in each solvent, over 18 min, 40 mL/min), and the combined pure fractions were lyophilized to give the title compound as a pale yellow solid (0.025 g, 31 %). MS (ESI, pos.): calc'd for C36H51CIN O10, 734.3; found 735.5 (M+H).
[00161] Step 4: Maytansin-3-N-methyl-L-(S)-alanine-propanamidyl-3-N-7nethyl~N-[4' (ainino~cit}-unine-valine^exanamide-6-maleimidyl)benzylJcai'bamate (7)
[00162] The product of the preceding step (6, 0.014 g, 0.019 mmol) and MA-VC-PAB- PNP (0.020 g, 0.027 mmol; Concortis Biosystems) were dissolved in 4: 1 acetonitrile/water (2.5 mL), treated with 0.1M aqueous NaHC03 (0.5 mL), and stirred at ambient temperature for 18 h. The reaction was purified directly by reverse-phase chromatography on C 18 silica (using 0.1% TFA in acetonitrile/water gradients). Lyophilization of the final column fractions gave the title compound as a white solid (0.002 g, 8%). MS (ESI, pos.): calc'd for
C65H89ClN,o018, 1332.6; found 1333.9 (M+H), 1316.5 (M-H20+H), 1355.9 ( +Na).
Figure imgf000046_0001
EXAMPLE 3
[00163] Step 1: 3-Methyldithio-propionic acid succinate ester (8)
[00164] The title compound was prepared as a white solid from 3-mercaptopropionic acid using the methods of Widdison et al. J. Med. Chem., 2006, 49 (14), 4392-4408. Ή NMR
(300 MHz, CDC13) δ 3.09 (m, 2H), 3.01 (m, 2H), 2.86 (s, 4H), 2.44 (s, 3H).
[00165] Step 2: Maytansin-3-N- ethyl-L-(S)-alaninepropanamidyl-3-methyldisulfide
(9)
[00166] The product of the preceding step (8, 2.96 g, 11.9 mmol) and maytansin-3-N- methyl-L-alanine (2, 1.54 g, 2.37 mmol) were dissolved in 4: 1 acetonitrile/water (25 mL), treated with saturated aqueous NaHC(¾ (2 mL), and stirred at ambient temperature for 24 hours. The reaction mixture was treated with brine, extracted thrice with EtOAc, the aqueous layer saturated with NaCl, extracted again with EtOAc, and the combined organic layers dried over Na2S04, and filtered. The filtrate was concentrated in vacuo to a gold syrup (ca.
4.5 g) that was purified by flash column chromatography on a 80g silica gel cartridge (0 -
100% EtOAc in hexanes over 30 min) giving the title compound as a white solid (1.14 g,
61%). MS (ESI, pos.): calc'd for CjeHsoClNsO!oSz, 783.3; found 784.3 (M+H), 766.6 (M- H2O TT).
[00167] Step 3: Maytansin-3-N-methyl-L-(S)-alanine-propanamide-3-ihiol (10)
[00168] The title compound was prepared using a modified version of the method described by Whitesides et al. (J. Org. Chem., 1991, 56, 2648-2650). The product of the preceding step (9, 2,42 g, 3.09 mmol) was dissolved in acetonitrile (30 mL), treated with a solution of tris(2-carboxyethyl)phosphine hydrochloride (8.23 g, 28.7 mmol) in water (30 mL), the pH raised to 3 with the addition of saturated aqueous NaHCOj (5 mL), the f!ask purged with Ar, and the reaction stirred at ambient temperature under a rubber septum (vented due to effervescence). After 2 hours, the reaction was treated with brine (ca. 100 mL), bubbled with Ar for 5 min (to remove the free methylmercaptan), and the phases separated. The aqueous phase was extracted twice with EtOAc, saturated with NaCl, and extracted twice more with EtOAc. The combined organic layers were then dried over NaiS04, filtered, and the filtrate concentrated and dried in vacuo to give the title compound as a white solid (2.24 g, 98%). MS (ESI, pos.): calc'd for CssLUsClNjOioS, 737.3; found 738.3 (M+H), 720.3 (M-H20+H).
[00169] Step 4: 4~Amino-(N-benzyloxycarbonyl)benzylamine (14) [00170] 4-Aminobenzylamine (1.00 g, 8.18 mmol) and triethylamine (1.20 mL, 8.61 mmol) were dissolved in anhydrous tetrahydrofuran (THF, 10 mL) under N2, cooled in a brine/ice bath with stirring, and treated dropwise over 20 min with a solution of benzyl chloroformate (1.20 mL, 8.41 mmol) in anhydrous THF (10 mL). After the addition was complete, the ice bath was removed and the reaction was stirred at ambient temperature for 20 hours, then filtered over a sintered glass funnel to remove insolubles. The solids were washed with EtOAc, the filtrate evaporated in vacuo, and the residue purified by flash column chromatography on a 40g silica gel column (0 - 100% EtOAc in hexanes, over 20 min, 40 lnL/min). Evaporation of the pure mid-running fractions in vacuo gave the title compound as a light yellow solid (1.47 g, 70%). MS (ESI, pos.): calc'd for Ci5Hi6N202, 256.1; found 256.9 (M+H), 278.9 (M+Na).
[00171] Step 5: 6-Maleimidylhexanoic acid succinate ester (20)
[00172] The title compound was prepared as a colorless gum from commercial 6- aminocaproic acid by a method similar to that of Marnett et al. (J. Med. Chem., 1 96, 39,
1692-1703). lH NMR (300 MHz, CDC13) 6 6.72 (s, 2H), 3.56 (t, 2H, J= 7 Hz), 2.86 (s, 4H),
2.64 (t, 2H, J= 7 Hz), 1.81 (pentet, 2H, J= 8 Hz), 1.66 (m, 2H), 1.45 (m, 2H).
[00173] Step 6: Boc-valine-succinate (11)
[00174] The title compound was prepared as a white solid from Boc-Val-OH by a method well known in the art (c.f- Widdison et al., J. Med. Chem., 2006, 49 (14), 4401). Ή MR (300 MHz, CDCI3) 5 5.03 (d, 1H, J= 10 Hz), 4.60 (dd, 1H, J= 9 Hz, 5 Hz), 2.85 (s, 4H), 2.32 (m, 1H), 1.47 (s, 9H), 1.05 (m, 6H).
[00175] Step 7: Boc-valine-citrulline (12)
[00176] The product of the preceding step (11, 4.23 g, 13.5 mmol) was dissolved in acetonitrile (70 mL), treated with a solution of L-citruIline (3.20 g, 18.3 mmol) in water (30 mL) and a saturated solution of NaHC<¾ (18 mL), flask purged with N2, and reaction stirred at ambient temperature for 24 hours. The mixture was concentrated in vacuo to remove the acetonitrile, washed once with EtOAc to remove nonpolar impurities, and the aqueous layer saturated with NaCl and acidified to pH 3 with 10% HC1. The resulting cloudy mixture was extracted four times with 10% isopropanol in EtOAc, the combined organic layers dried over Na2S0 , and filtered. Concentration and drying of the filtrate in vacuo gave the title compound as a white solid (4.53 g, 90%). MS (ESI, neg.): calc'd for C16H3oN406, 374.2; found 373.0 (M-H). [00177] Step 8: Boc-vaUne-citrulline-amino-4-benzylamino-N-benzyloxycarbamate (15)
[00178] The product of the preceding step (12, 3.08 g, 8.23 mmol) was dissolved in N,N- dimethylformamide (DMF, 30 mL, dried over molecular sieves), treated with
dicyclohexylcarbodiimide (DCC, 2.31 g, 11.2 mmol) and 1-hydroxybenzotriazole hydrate (HOBt, 1.51 g, 11.2 mmol), the flask purged with N2 and stirred at ambient temperature for 1 hour. A solution of 4-amino-(N-benzyloxycarbonyl)benzylamine (14, 2.30 g, 8.97 mmol) in DMF (15 mL) was then added, the reaction stirred another 3 days, filtered over a sintered glass funnel, and solids washed with ethyl acetate. The filtrate was washed with 1 : 1 water/saturated NaHC03 (100 mL), the aqueous layer extracted thrice with 10%
isopropanol/EtOAc, and the combined organic layers washed with brine, dried over N .2SC>4, and filtered. During filtration an insoluble gel formed that was dissolved with
methanol/EtOAc. Concentration of the filtrate in vacuo gave a gummy gold gel that was treated with diethyl ether (50 mL), sonication, filtered, and suction-dried to a pale yellow solid. This was purified by flash column chromatography on a 330g silica gel column (0 - 10% methanol in dichloromethane, 100 lnL/min) giving the title compound as a pale yellow solid (4.07 g, 81%). MS (ESI, pos.): calc'd for C31H44N6O7, 612.3; found 613.4 (M+H)
[00179] Step 9: Boc-valme-citrullme-amino-4~benzyl nine (16)
[00180] The product of the preceding step (15, 3.04 g, 4.96 mmol) and 10% palladium (0) on activated charcoal (0.286 g, 0.269 mmol) were treated under N2 stream with methanol (50 mL) and glacial acetic acid (0.57 mL, 9.95 mmol), the reaction bubbled a few minutes each with N2 then hydrogen, and stirred vigorously under a hydrogen balloon at ambient temperature and pressure for 1 hour. When the reaction was complete by TLC, the balloon was removed, the suspension bubbled several minutes with N2, and filtered over Celite 521. The Celite was washed with methanol, the filtrate evaporated to dryness in vacuo, and the residue triturated once with diethyl ether and dried under high vacuum giving the title compound as a white solid (2.95 g, 99%). MS (ESI, pos.): calc'd for C23t½N605, 478.3; found 479.2 (M+H).
[00181] Step 10: Boc-valine-citrulline-amino-4-henzylisothiocyanate (17)
[00182] The product of the preceding step (16, 0.586 g, 0.979 mmol) was dissolved in dry tetrahydrofuran (20 mL) and dry N,N-dimethylformamide (5 mL) under N2, treated with triethylamine (0.40 mL, 2.87 mmol), cooled in an ice bath, and treated dropwise with carbon disulfide (0.10 mL, 1.66 mmol) over 5 min. The reaction was warmed to ambient temperature and stirred for 2 hours, cooled again in ice, and treated with p-toluenesulfonyl chloride (0.281 g, 1.47 mmol). After warming to ambient temperature and stirring for 18 hours, the reaction was washed with 1 : 1 water/brine, extracted twice with ethyl acetate, the aqueous layer saturated with NaCI, extracted twice more with EtOAc, and the combined organic layers washed with brine, dried over N 2S04, and filtered. The evaporated filtrate was purified by flash column chromatography on a 20g silica gel column (0 - 100% acetonitrile in EtOAc, 35 mL/min) giving the title compound as a gold solid (0.391 g, 77%) after azeotroping with dichloromethane and drying under high vacuum. MS (ESI, pos.): calc'd for C2 H36N6O5S, 520.3; found 521.1 (M+H).
[00183] Step 11: Maytansin-3-N-methyl-L-(S)-alanine-propanamidyl-3-N-[4-(amino- citfuUine-Boc-valine) -benzyl] -dith iocarbamate (18)
[00184] The product of the preceding step (17, 0.068 g, 0.13 mmol) and maytansin-3- N-methyl-L-(5)-alanine-propanamide-3 -thiol (10, 0.048 g, 0.065 mmol) were dissolved in dry THF (3 mL) under Ar, treated with triethylamine (0.050 mL, 0.359 mmol) via syringe, and stirred at ambient temperature under rubber septum for 18 hours. The reaction was concentrated in vacuo, dissolved in 10% isopropanol/ethyl acetate, and washed with 0.5N aq. HCl. The aqueous layer was extracted thrice with 10%) IPA/EtOAc, combined organic layers washed with brine, dried over N 2S0 , and filtered. The evaporated filtrate was purified by flash column chromatography on a 12g silica gel column (0 - 20% methanol in EtOAc, 30 mL/min) giving the title compound as a white solid (0.042 g, 51%). MS (ESI, pos.): calc'd for C59H84CIN9O15S2, 1257.5; found 1258.8 (M+H), 1241.5 (M-H20+H), 1280.6 (M+Na).
[00185] Step 12: Mayta in-3-N- ethyl-L-(S)-alanine-propanamidyl-3-N-[4-(amino- citrulline-valine)-benzyl]-dithiocarbamate (19)
[00186] The title compound was prepared as a gold solid (0.016 g, 100%) from the product of the preceding step (18, 0.014 g, 0.011 mmol) by the method of Example 2, Step 3 (compound 6). The compound was used without further purification. MS (ESI, pos.): calc'd for C54H76ClN9Oi3S2, 1 157.5; found 1 159.4 (M+H).
[00187] Step 13: Maytansin-3-N-methyl-L-( )-alanine-propanamidyl-3-N-[4-(amino- citrulline-valine-hexanamide-6-maieimidyl)benzyl]-dithiocarbamate (21)
[00188] The product of the preceding step (19, 0.055 g, 0.032 mmol) was dissolved in 1 :1 acetonitrile/water (4 mL), treated with IN aq. NaHC03 (0.5 mL) and a solution of 6- maleimidylhexanoic acid succinate ester (20, 0.070 g, 2.27 mmol) in acetonitrile (6 mL), and the flask purged with Ar under rubber septum. After the reaction stirred at ambient temperature for 5 hours, it was stored at -20°C for 3 days before warming again to ambient temperature and diluting with brine. The mixture was extracted thrice with ethyl acetate, combined organic layers dried over N 2S<¾, and filtered. The evaporated filtrate was purified by flash column chromatography on a 12g silica gel column (0 - 20% methanol in EtOAc over 18 min, 25 mL/min) giving the title compound as a pale yellow solid (0.01 1 g, 26%). MS (ESI, pos.): calc'd for
Figure imgf000051_0001
1350.5; found 1352.0 (M+H), 1334.5 (M- H20+H), 1373.5 (M+Na).
Figure imgf000051_0002
Figure imgf000052_0001
21
EXAMPLE 4
[00189] Step 1: N-(4-Aminomethyl-phenyl)-acetamide hydrochloride (23)
[00190] The title compound was prepared as a light yellow solid from 4- aminobenzylamine by the method of King et al. (J. Am. Chem. Soc, 1992, 114{K), 3033). Ή NM (300 MHz, DMSO-d5): δ 10.18 (s, 1 H), 8.36 (br s, 3H), 7.63 (d, 2H, /= 8.7 Hz), 7.41 (d, 2H, J= 8.7 Hz), 3.95 (s, 2H), 2.06 (s, 3H).
[00191] Step 2: N-(4-Isothiocyanatomethyl-phenyl)-aeetamide (24)
[00192] The product of the preceding step (23, 0.277 g, 1.38 mmol) was dissolved in THF (4.5 mL) and DMF (2.0 mL), cooled in ice under N2, treated with triethylamine (0.66 mL, 4.73 mmol), then treated dropwise with carbon disulfide (0.125 mL, 2.07 mmol). The reaction was warmed to ambient temperature, stirred for 3 hours, then cooled again in ice. After treating with p-toluenesulfonyl chloride (0.274 g, 1.45 mmol), the reaction slowly warmed to ambient temperature while stirring for 18 hours. The mixture was diluted with water, acidified to pH 2 with 10% aq. HCl, and extracted thrice with EtOAc. The combined organic layers were washed with brine, dried over NaiSO,), and filtered. The evaporated filtrate was purified by flash column chromatography on a 20g silica gel column (0 - 50% acetonitrile in EtOAc over 20 min, 30 mL/min) giving the title compound as a cream-colored solid (0.157 g, 55%). 'H NMR (300 MHz, CDC13) δ 7.55 (d, 2H, J = 8.7 Hz), 7.29 (m, 3H), 4.70 (s, 2H), 2.23 (s, 3H).
[00193] Step 3: Maytansin-3-N-methyl»L~(&)-alanine^ropanamidyl-3-N-[4- (acetamidyl) benzyl] -dithio-carbamate (25) [00194] The product of the preceding step (24, 0.093 g, 0.45 mmol) and the product of Example 3, Step 3 (10, 0.070 g, 0.095 mmol) were dissolved in acetonitrile (MeCN, 2 mL) and dry DMF (1 mL), and treated with basic alumina (activated, Brockniann I, 0.357 g). After purging the flask with argon, the reaction was stirred at ambient temperature for 2 days, filtered, and the solids washed with methanol/acetonitrile. The evaporated filtrate was purified by flash column chromatography on a 12g silica gel column (0 - 50% acetonitrile in EtOAc over 15 min, 25 mL/min) and the slower product fractions concentrated in vacuo to an impure pale yellow gum. This was purified by RP-HPLC (Phenomenex Gemini CI 8, 30x150mm column, 30 - 90% acetonitrile in water, 0.1% TFA in both) and the pure fractions were lyophilized giving the title compound as a white solid (0.016 g, 18%). MS (ESI, pos.): calc'd for C+sHjgClNsOiiSs, 943.3; found 944.7 (M+H), 927.1 (M-H2OH), 966.6 (M+Na).
Figure imgf000053_0001
25
EXAMPLE 5
[00195] Maytansin-3-N-methyl-L-(S)-alanine^-alanine (27)
[00196] The title compound was prepared as a pale yellow solid from 2,5- dioxopyrrolidin-l-yl 3-((tert-butoxycarbonyl)amino)propanoate (26) by the method of
Example 2, Steps 1 -3. MS (ESI, pos.): calc'd for C35H49C1N4O10, 720.3; found 721.4
(M+H).
Figure imgf000054_0001
EXAMPLE 6
[00197] Maytansin-3-N-methyl-L-(S)-alanine→ γ-aminobutyramide (29)
[00198] The title compound was prepared as a pale yellow solid from N-Boc-GABA-OH (28) by the method of Example 2, Steps 1-3. MS (ESI, pos.): calc'd for C36H51CIN O10, 734.3; found 735.5 (M+H).
Figure imgf000054_0002
EXAMPLE 7
[00199] Maytarisin-3-N-methyl-L-(S)-alanine-N~Me- -amhwbutyramide (31)
[00200] The title compound was prepared as a pale yellow solid from N-Boc-N-Me GABA-OH (30) by the method of Example 2, Steps 1-3. MS (ESI, pos.): calc'd for C37H53C1N4O10, 748.4; found 749.5 (M+H).
Figure imgf000054_0003
EXAMPLE 8
[00201] Step 1: Maytmsin-3-N-methyl-L-(S)-alanine-N-carboxy-6-[3,4-dihydro-2-(tert- butoxycarbonyl) -lH-isoquinoline ]
[00202] Maytan-3-N-methyl-L-(S alanine (2, 0.034 g, 0.052 mmol), commercial N- Boc-l,2,3,4-tetrahydroisoquinoHne-6-carboxylic acid (32, 0.019 g,0.069 mmol), and l-(3- Dimethyiaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.024 g, 0.125 mmol) were weighed into a round-bottom flask with stir bar, dissolved in dichloromethane (3 mL), the fl sk purged with Ar and sealed with a rubber septum, and the reaction stirred at ambient temperature. After 2 days, the reaction was diluted with EtOAc and washed with dilute aq. NaHC03, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2S04, and filtered. The evaporated filtrate was then purified on a 12g RediSep Gold silica gel column via ISCO system (EtOAc - 5:5:1 EtOAc/DCM MeOH over 12 mins, 30 mL/min), and the combined TLC-pure fractions evaporated and dried in vacuo giving the title compound as a pale solid (0.026 g, 55%). MS (ESI, pos.): calc'd for C47H61C1N4012, 908.4; found 909.2 (M+H), 891.2 (M-H20+H).
[00203] Step 2: Maytamin-3-N-methy!-L-fi)-alanine-N-carboxy-6-(l, 2,3,4- tetrahydroisoquinoline) (33)
[00204] The title compound was prepared as a white solid (0.013 g, 52%) from the product of the preceding step (0.025 g, 0.027 mmol) by the method of Example 2, Step 3 (compound 6). MS (ESI, os.): calc'd for C42H53Cl found 809.2 (M+H).
Figure imgf000055_0001
33
2 EXAMPLE 9
[00205] Step 1: Maytansm-3-N-methyl-L-(S)-alanine- N-carboxy-4-fl-(tert- butoxycarbonyl) -piperidine ]
[00206] The title compound was prepared as a white solid (0.027 g, 46%) from maytan- 3-N-methyl-L-(5)-alanine (2, 0.045 g, 0.069 mmol) and commercial 1-t- butoxycarbonylpiperidine-4-carboxylic acid (34, 0.024 g,0.105 mmol) by the method of Example 8, Step 1. MS (ESI, pos.): calc'd for C43¾1C1N4012, 860.4; found 861.2 (M+H), 843.2 (M-H20+H).
[00207] Step 2: Maytansin-3-N-methyl-L-(&)-alanine- N-carboxy-4-piperidine (35)
[00208] The title compound was prepared as a white solid (0.012 g, 50%) from the product of the preceding step (0.025 g, 0.029 mmol) by the method of Example 2, Step 3 (compound 6). The compound purified on a CI 8 column using a different gradient and modifier (20 - 80% MeCN in water, 0.05% acetic acid in both). Lyophilization of the pure fractions gave the title compound (0.008 g, 35%). MS (ESI, pos.): calc'd for C38H53CIN4OK), 760.3;
Figure imgf000056_0001
2 35
EXAMPLE 10
[00209] Step 1: Maytansin- 3 -N-methyl-L-(S) -alanine- N-methyl-beta-alanine-N-[4- (tert-butoxycarbonyl-valine-citrultine-amino)benzyloxy]-carbamate
[0021Θ] The Boc-valine-citrulline-p-aminobenzyloxy-(p-nitrophenyloxy)-carbonate (36), prepared according to WO 2005112919, (0.092 g, 0.143 mmol), the product of Example 2, Step 3 (6, 0.1 10 g, 0.130 mmol), and l-Hydroxy-7-azabenzotriazole (HOAT, 0,037 g, 0.272 mmol) were dissolved in DMF (7 mL), treated with triethylamine (0.100 mL, 0.717 mmol), and stirred at ambient temperature in a stoppered flask. After 18 hours, the reaction mixture was concentrated to an oil in vacuo, dissolved in dichloromethane, and purified on a 24g RediSep Gold column via ISCO Combiflash (0 - 20% methanol in ethyl acetate). Evaporation of the product fractions in vacuo then gave the title compound as a pale yellow solid (0.129 g, 80%). MS (ESI, pos.): calc'd for C50H86ClN9Oi7, 1239.6; found 1240.8 (M+H).
[00211] Step 2: Maytansin-3-N-methyl-L-(&)-alanine- N-methyl-beta-alanine-N-[4- (valine-cUrulline-amino)benzyloxy]-carbamate (37)
[00212] The title compound was prepared as a white solid (0.074 g, 63%) from the product of the preceding step (0.128 g, 0.103 mmol) by the method of Example 2, Step 3 (compound 6). MS (ESI, pos.): calc'd for CssHygCINsOjs, 1 139.5; found 1141.4 (M+H).
[00213] Step 3: Maytansin- 3 -N-methyl-L-(&) -alanine- N-methyl-beta-alanine-N-[4- (4- {isothiocyanato-phenyl}-thioureido-vali -citrulline-amino )benzyloxy] -carbamate (39)
[00214] The product of the preceding step (37, 0,037 g, 0.029 mmol) was dissolved in tetrahydrofuran (THF, 5 mL) in a vial, treated with triethylamine (0.020 mL, 0.143 mmol), and the resulting solution added dropwise to a flask containing a stirred solution of 1,4- phenylenediisothiocyanate (38, 0.055 g, 0.286 mmol) in THF (10 mL) over 15 min. The vial was rinsed with THF (2 mL) and the solution added to the reaction flask, which was sealed, with a rubber septum. After stirring at ambient temperature for 24 hours, the reaction was concentrated in vacuo to dryness, the crude product dissolve in acetonitrile, and filtered over a 0.45 um PTFE membrane. The filtrate was then purified on a 30 g C18 RediSep Gold column via ISCO (20 - 80% MeCN in water, 0.05% HOAc in both solvents) and the purest fractions (by LC) combined, frozen at -78°C, and lyophilized giving the title compound as white solid (0.023 g, 59%). MS (ESI, pos.): calc'd for Q^CINnO^, 1331.5; found 1332.0 (M+H).
Figure imgf000058_0001
EXAMPLE 11
[00215] Step 1: l-(4-Arnino~butyl)-maleirnide
[00216] A solution of commercial Boc- 1 -aminobutyl-4-maleimide (0.304 g, 1.13 mmol) in dichloromethane (10 mL) was treated with trifluoroacetic acid (1.00 mL, 13.1 mmol), the flask purged with Ar, sealed with a rubber septum and bubbler vent, and stirred at ambient temperature. The reaction was complete by TLC after 18 hours, so it was concentrated in vacuo, triturated twice with diethyl ether, and dried in vacuo to a gum. This was triturated twice more with ether (while scraping with a spatula), decanted, and dried again in vacuo giving the title compound as a white solid (0.321 g, 100%). MS (ESI, pos.): calc'd for CgH,2N2023 168.1 ; found 169.0 (M+H).
[00217] Step 2: l-(4-Isothiocyanato-butyl)-maleimide (41)
[00218] The product of the preceding step was dissolved in acetonitrile (MeCN, 3 x 40 mL) and concentrated in vacuo at 60° C via rotary evaporator. The dried product (0.650 g, 2.45 mmol) was dissolved in MeCN (75 mL) and chloroform (30 mL) in a flask, treated with triethylamine (1.0 mL, 7.35 mmol), and the resulting solution added dropwise to a flask containing 1 , 1 l-thiocarbonyldi-2,2,-pyridone (0.68 g, 2.94 mrnol) in chloroform (25 mL) under nitrogen over 10 min. The reaction was stirred at ambient temperature for 18 hours, the reaction was concentrated in vacuo to dryness, the crude product was dissolved in dichloromethane (DCM) and purified on a 120 g silica gel RediSep Gold column via flash column chromatography (0 - 10% MeOH in DCM). The cleanest fractions (by LC) were combined and concentrated to dryness giving the title compound as white solid (0.26 g, 50%). MS (ESI, pos.): calc'd for C9H,oN202S, 21 .0; found 21 1.2 (M+H).
[00219] Step 3: Maytansin-3-N-methyl-L-(S)-alanme~ N-methyl-beta-alanine-N~[4- (4- {maleimidylbutylj-thioureido-valine-citrullin^ (42)
[00220] The product of Example 10, Step 2 (37, 0.029 g, 0.023 mrnol) was dissolved in dry DMF (2 mL), treated wit diisopropylethylamine (0.020 mL, 0.1 15 mmol) via dry syringe, then with a solution of product of the preceding step (41, 0.026 g, 0.124 mmol) in dry DMF (2 mL). The reaction flask was purged with Ar, sealed with a rubber septum, and the reaction stirred at ambient temperature. After 18 hours the reaction appeared to be 80% complete by LCMS, so it was evaporated to an oil in vacuo, dissolved in MeCN/water, and purified on a 30g C18 RediSep Gold column via flash column chromatography (20 - 80% MeCN in water, 0.05% HOAc in both solvents). The cleanest fractions by LCMS were combined, briefly rotavapped, frozen on dry ice, and lyophilized overnight giving the title compound as a white solid (0.020 g, 65%). MS (ESI, pos.): calc'd for
Figure imgf000059_0001
1349.6;
Figure imgf000059_0002
42 EXAMPLE 12
[00221] Conjugate Preparation and Characterization
[00222] For the initial set of experiments, four antibodies were conjugated to various linker-drug compounds of the disclosure using the procedure below. The four antibodies used in these experiments were: (1) a PSMA antibody having the heavy and light chain variable domains of clone AB-PG1-XG 1-006 as set forth in WO 2007002222A2, (2) a STEAP1 antibody having the heavy and light chain variable domains of clone mul20, expressed as a hlgGl, as set forth in WO 2008052187A2, (3) an EGFRvIII antibody having the heavy and light chain variable domains of clone 131 as set forth in WO2013075048A1, and (4) a PRLR having the heavy and light chain variable domains of clone H1H6953N as set forth in US Application Serial No. 61/868,185; filed on August 21, 2013 (the disclosure of which is hereby incorporated by reference in its entirety). All the monoclonal antibodies were expressed in CHO cells and purified by Protein A. A non-binding control derived from an immunological antigen having no relation to oncology was also used.
[00223] Conjugation Method for Compounds 3, 7, 21 and 42
[00224] The antibody (10 mg ml) in 50 mM HEPES, 150 mM NaCl, pH 7.5, was treated with 1 mM dithiothreitol at 37° C for 30 min. After gel filtration (G-25, pH 4.5 sodium acetate), the maleimido linker payload derivative (1.2 equivalents/SH group) in DMSO (10 mg ml) was added to the reduced antibody and the mixture adjusted to pH 7.0 with 1 M HEPES (pH 7.4). After 1 h the reaction was quenched with excess N-ethyl maleimide. The conjugates were purified by size exclusion chromatography and sterile filtered. Protein and linker payload concentrations were determined by UV spectral analysis. Size-exclusion HPLC established that all conjugates used were >95% monomeric, and RP-HPLC established that there was <0.5% unconjugated linker payload. Yields are reported in Table 1 based on protein. All conjugated antibodies were analyzed by UV for linker payload loading values according to Hamblett et al, Cancer Res., 2004 10 7063. The results are summarized in Table 1.
[00225] Conjugation Method for Compound 39
[00226] To the antibody (2-5 mg ml) in 50 mM carbonate, 150 mM NaCl, pH 9.0, was added 15% by volume dimethyl acetamide. The linker payload derivative 39 (5-10 equivalents) in DMSO (10 mg/ml) was added to the antibody and the mixture incubated at 37° C for 4-12 hours. The conjugates were purified by size exclusion chromatography and sterile filtered. Protein and linker payload concentrations were determined by UV spectral analysis. Size-exclusion HPLC established that all conjugates used were >95% monomeric, and RP-HPLC established that there was <0.5% unconjugated linker payload. For these conjugates, the payload to antibody ratio was determined by MALDl-TOF (Table 1).
Table 1
Compound 8252 nm (cm 1 "1} 6280 nm (cm 1 M"1)
3 32000 8500
7 50600 8100
21 44190 9460
39
Antibody ε252 nm (cm 1 Wl"1} E280 nm (cm 1 M"1)
STEAP1 87939 244276
PSMA 77652 224320
PRLR 80673 220420
EGFRvill 79579 209420
Isotype Control 75113 218360
Antibody Conjugate Payload :Antibody (UV) Yield %
STEAP1-7 1.4 36
PSMA-3 3.5 44
PSMA-7 3.4 60
PSMA-21 0.9 45
PRLR-7 3.0 70
EGFRvNI-7 3.4 64
EGFRvlll-39 1.3 (MALDI) 40
Isotype Control-3 3.0 48
Isotype Controls 2.3 51
Isotype Control-21 2.3 45
Isotype Control-39 1.1 (MALDI) 40 EXAMPLE 13
[00227] In Vitro Antibody-Drug Conjugate (ADC) Cell-free Enzymatic Assays
[00228] Cathe sin B incubation
[00229] In vitro cell-free enzymatic assay procedure was adopted from Dubowchik, et al., Bioconjugate Chem. 2002 13 855. The DAR corrected PRLR-7 and Isotype Control-7 concentration was set to 7.00 uM in 25 mM sodium acetate buffer, 1 mM EDTA, pH 5.0 and pre-incubated at 37°C. Cathepsin B (Sigma # C8571) was activated at room temperature for 15 minutes with 1 equivalent of 30 mM DTT, 15 mM EDTA to 2 equivalents of cathepsin B stock. The activated cathepsin B solution was added to the ADC solutions at a 1 :750 molar ratio. Samples were incubated at 37° C over a 24 hour period and aliquoted for either HPLC (HISEP)-UV detection or LC-MS detection vide infra.
[00230] LC-MS detection
[00231] At designated time points, a small aliquot was removed and combined with 2 equivalents by volume of cold methanol. Supernatant was recovered and analyzed by liquid chromatography-mass spectrometry (LCMS) for cathepsin B linker payload cleavage yielding compound 6 using a Merck Chromolith FastGradient RP-18e, 2x50 mm column, 10 to 90% MeCN over 5 mins, in ¾0 with 0.05% HOAc in both solvents and a flow rate of 1 mL. The elution profile was monitored at 254 nm. All of the aliquots incubated at 37°C with cathepsin B contained compound 6 eluting at 5.1 minute with a mass of 735 M+H (calc'd for C36H51C1N4O10, 734.3) and none of the aliquots without cathepsin B contained any 6. This was also confirmed by injection of pure compound 6 from Example 2, step 3.
[00232] HPLC fHISEPVUV detection
[00233] Solutions were injected "as is" at designated time points. The following gradient method was utilized: buffer A 100% 100 mM NH40Ac, pH 7.0 and buffer B 100% acetonitrile, flow rate 0.4 mL/min, from 5 to 70% buffer B, over a Supelco LC-HISEP; 150 mm x 4.6 mm, column. The elution profile was monitored at 280 nm and 252 nm. All aliquots of the cathepsin B incubated ADCs contained a species which elutes at 19.4 minute. Pure compound 6 elutes at the identical retention time under the same gradient conditions. The 1 .4 minute species was not present in the aliquot without cathepsin B.
[00234] The results of this Example are significant in part because cathepsin B proteolysis of 6 should only occur after internalization of the ADC in the cell where the enzyme exists. Off target effects should be reduced since the antibody delivers the cytotoxic payload directly to targeted cells.
EXAMPLE 14
[00235] In Vitro Cytotoxicity Assays
[00236] In this Example, the ability of various antibody-drug conjugates to kill antigen- expressing tumor cells in vitro was assessed.
[00237] Cells were seeded in PDL-coated 96 well plates at 375 (MMT/hEGFRvIII), 1500 (U251/hEGFRvHI), 2000 (JrIEK293/hEGFRvlH), or 3000 (C4-2, PC3/hSTEAPl, T47D, and U87-MG) cells per well in complete growth media and grown overnight. For cell viability curves, serially diluted conjugates or free representative payloads were added to the cells at final concentrations ranging from 500 nM to 1 pM and incubated for 3 days. To measure viability in MMT/hEGFRvIII, U251/hEGFRvIII, HEK293/hEGFRvIll, C4-2, PC3/hSTEAPl, and U87-MG, cells were incubated with CCK8 (Dojindo) for the final 1-3 hours and the absorbance at 450nm (OD450) was determined on a Flexstation3 (Molecular Devices). To measure viability in T47D, cells were incubated on ice for 30 min in 4% formaldehye + 3ug/ml Hoechst. Images of Hoechst stained nuclei were acquired on the ImageXpress Micro XL (Molecular Devices) and nuclear counts were determined with the Columbus analysis software (PerkinElmer). Background OD450 levels (CC 8) or nuclear counts from digitonin (40 nM) treated cells were subtracted from all wells and viability is expressed as a percentage of the untreated controls. IC50 values were determined from a four- parameter logistic equation over a 10-point response curve (GraphPad Prism). All curves and IC50 values are corrected for payload equivalents.
[00238] In C4-2 cells (prostate cancer line), natively expressing PSMA at 271 fold above isotype control binding, the maytansinoid conjugates PSMA-3, PSMA-7, and PSMA-21 possess IC50 values of 3.8, 0.5, and 8.3 nM, respectively (Figure 1). The naked PSMA antibody was devoid of any anti-proliferation activity.
[00239] In PC3/hSTEAPl cells (prostate cancer line), expressing hSTEAPl at 352 fold above isotype control binding, the maytansinoid conjugate STEAP1-7 possesses an IC50 value of 4 nM (Figure 2). The naked STEAP1 antibody was devoid of any anti-proliferation activity. [00240] In T47D cells (breast cancer line), natively expressing PRLR at 14 fold above isotype control binding, the maytansinoid conjugate PRLR-7 possesses an IC50 value of 1 ,0 nM (Figure 3). The naked T47D antibody was devoid of any anti-proliferation activity.
[00241] In HE 293/hEGFRvIII cells, expressing hEGFRvIII at 360 fold above isotype control binding, the maytansinoid conjugate EGFRvIII-7 possesses an IC50 value of 0.4 nM (Figure 4). The naked EGFRvIII antibody was devoid of any anti-proliferation activity.
[00242] In MMT/hEGFRvIII cells, expressing hEGFRvIII at 280 fold above isotype control binding, the maytansinoid conjugate EGFRvIII-7 possesses an IC50 value of 0.3 nM (Figure 5). The naked EGFRvIII antibody was devoid of any anti-proliferation activity.
[00243] In U251 /hEGFRvIII cells (glioblastoma cancer line), expressing hEGFRvIII at 165 fold above isotype control binding, the maytansinoid conjugate EGFRvIII-7 possesses an 1C50 value of 0.3 nM (Figure 6). The naked EGFRvIII antibody was devoid of any anti- proliferation activity.
[00244] In vitro cytotoxicity of proposed released payloads ("free drugs") were also tested in the various cell lines described above and plotted along-side the conjugated antibodies for comparison (see closed squares (■) in Figures 1 to 6). For linker-payloads 3 and 7 the proposed released payloads 2 and 6, respectively, can be used in the cellular assays directly since they are stable. However, for linker-payload 21 the released payload is proposed to be the sulfhydryl compound 10. Since 10 could be a very reactive compound, which would lead to unreliable results, compound 25 was chosen to represent the released payload in these assays.
[00245] In a separate set of experiments, compound 6, along with amino analogs 27, 29, and 31 were assayed in HEK293 and U87MG for anti-proliferation activity (Figure 7). These compounds all had >30 nM IC50 values indicating that they are highly cytotoxic only when attached to an antibody via an appropriate linker. (For these experiments, background correction with digitonin was not performed).
[00246] In yet another set of experiments, compounds 6, 9, 33, and 35 were assayed in HEK293, U251, C4-2, PC3, and MMT for anti-proliferation activity (Figure 8). Amino compounds 6, 33, and 35 had varied IC50s as listed in Table 2. The trend in potency follows 9 > 33 > 35 > 6 and is consistent for the 5 cell lines assayed. Table 2 IC50 (n )
Compound HEK293 U251 C4-2 PC3 MT
9 0.2 0.4 1.5 0.4 0.3
33 20 15 20 30 20
35 50 25 55 65 60
6 200 150 200 250 250
[00247] Without being bound by any theory, the results of these experiments demonstrate that the "released" or "free drug" versions of the compounds of the present disclosure (i.e., the compounds not conjugated to an antibody) were, in most cases, substantially less cytotoxic than when conjugated to a targeting antibody. This feature of the present disclosure suggests that antibody-drug conjugates comprising the compounds of the invention will cause fewer side-effects and less unwanted toxicity since the cell killing properties will be concentrated at the site of the target antigen specifically.
EXAMPLE 15
[00248] Anti-EGFRvIII Antibody Drug Conjugates are Potent Inhibitors of Tumor Growth in in vivo EGFRvIII Positive Breast Cancer Allograft Models
[00249] In this Example, two different antibody-drug conjugates of the exemplary anti- EGFRvIII antibody H1H1863N2 were tested for their ability to inhibit tumor growth in vivo. (The amino acid sequence and various properties of H 1H1863N2 are set forth in US 61/950,963, filed on March 11, 2014, hereby incorporated by reference in its entirety). H1H1863N2 comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: l; a light chain variable region (LCVR) comprising SEQ ID NO:5; heavy chain complementarity determining regions (HCDRl , HCDR2 and HCDR3) comprising SEQ ID NOs: 2, 3 and 4, respectively; and light chain complementarity determining regions (LCDR1 , LCDR2 and LCDR3) comprising SEQ ID NOs: 6, 7 and 8, respectively.
[00250] A first ADC was produced by conjugating H1H1863N2 to the maytansinoid DM1 via a non-cleavable MCC linker {see, e.g., US 5,208,020 and US application
20100129314) to produce "H1H1863N2-MCC-DM1 ." A second ADC was produced by conjugating H1H1863N2 to 7 to yield "H1H1863N2-7." When tested for cytotoxicity in vitro against MMT EGFRvlII cells using the assay format described in Example 14, H1H1863N2- MCC-DM1 exhibited an IC50 of 12 nM whereas H1H1863N2-7 exhibited an IC5o of only 0.8 nM. Thus, in vitro, the anti-EGFRvIII ADC H1H1863N2-7 exhibited much more potent tumor cell killing ability than the corresponding antibody conjugated to DM1 via an MCC linker.
[00251] To compare the in vivo efficacy of the anti-EGFRvIII antibodies conjugated to MCC-DMl and 7, studies were performed in immunocompromised mice bearing EGFRvIII positive breast cancer allografts. Briefly, tumor allografts were established by subcutaneous implantation of 0.5xl06 MMT/EGFRvlII cells into the left flank of female CB17 SCID mice (Taconic, Hudson, NY). Once tumors had reached an average volume of 140 mm3 (~Day 8), mice were randomized into groups of seven, and dosed with anti-EGFRvIII ADCs using either the MCC-DMl or 7 linker-drug format. Control reagents, including non-binding ADCs using either the MCC-DMl or 7 linker-drug format, and PBS vehicle were also assessed. ADCs were dosed at 1 and 5 mg kg three times over one week and thereafter monitored until an average tumor size of approximately 2000 mm3 was attained in the group administered with vehicle alone. At this point the Tumor Growth Inhibition was calculated.
[00252] Average tumor size relative to the vehicle treated group were calculated as follows: tumors were measured with calipers twice a week until the average size of the vehicle group reached 1000mm3; tumor size was calculated using the formula (length x width2)/2. Tumor growth inhibition was calculated according to the following formula: (1- (( fina]-Tit,itjai)/(Cfinai-CiI,jtiai)))* 1005 where T (treated group) and C (control group) represent the mean tumor mass on the day the vehicle group reached 1000mm3. Results are summarized in Table 3.
Table 3: Tumor Size and Tumor Growth Inhibition Following Administration of Anti- EGF vIII Antibody-Drug Conjugates and Controls, administered in repeat dose
Figure imgf000067_0001
[00253] As shown in this Example, the greatest tumor inhibition was observed in mice dosed with 5 mg/kg H1H1863N2-7, where regression of the initial tumor was observed. The tumor growth inhibition of 102% resulting from treatment with 5 mg/kg H1H1863N2-7 was significantly greater relative to that observed following treatment of tumor with 5 mg/kg H1H1862N2-MCC-DM1 (83%). The superiority of the tumor growth inliibition induced by H1H1863N2-7 compared to H1H1863N2-MCC-DM1 was maintained at the 1 mg/kg dose as well. No anti-tumor effect was observed in groups treated with Control ADC using MCC- DM1 or 7.

Claims

What is claimed is:
1. A compound of Formula (I)
Figure imgf000068_0001
wherein:
L is absent or a Ligand;
further wherein:
when L is a Ligand, L is capable of binding to a cell or cell population;
a is an integer from 1 to 10;
7,2 and Zi are each independently absent or a spacer;
D is a Biologically Active Molecule;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids;
W is absent, -0-, -S-, -CRsRs-, -NR4-;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted;
Figure imgf000068_0002
wherein Ai, A3, Ri and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-„ -C(=0)-0-, -0-C(=0)-0-, -C(=0> (CH pi-, -C(=0)-0-(CHx)pl-, -(CHx)pl-C(=0 , -(CHx)p)-C(=0)-0-, -(0-(CH2)p2-)P3-, - ((CH2)P2-0-)P3-, -C(=S , -C(=S)-S-, -S-C(=S)-, -C(=S)-NH-, -S-C(=S)-S-, -S-, -SO-, -S02-, - NR4-,
Figure imgf000068_0003
-C(=0)-
Figure imgf000069_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A and A5 are each independently -0-, -S-, -ΝΙ½-, -CR5R.6-;
Ri is selected from the group consisting of O, S, ½, CRsRfi ;
Ris is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
Rt, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
i, p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
2. The compound of claim 1 , wherein D is a cytotoxic agent.
3. in the cytotoxic agent is maytansinoid of formula II:
Figure imgf000069_0002
wherein A7, Ag, A9 are each independently absent, an amino acid, N-alkyl amino acid, a peptide having 2-20 amino acids, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -OC(=0)-, -C(=0)-0-, -0-C(0)-
Figure imgf000069_0003
)P3-, -((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-S -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, - SO2-, -NR4-, -N(R4)-C(=0)-N(RS)-, -N(R4)-C(=0)0-, -N(R )-C(=0)-, -C(=0)-N(l¾4)-t - C(=0)-N(R4)"C(=0)-, -0-C(=0)-NR4, further wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and R4, R5, ¾, g are as defined in claim 1.
4. The compound of claim 3, wherein the maytansinoid is represented by the following structural formula:
Figure imgf000070_0001
5. The compound of claim 1 , wherein L is capable of binding to a specifically targeted cell population.
6. The compound of claim 1 , wherein L is selected from the group consisting of proteins, antibodies, fragments of antibodies, nucleic acids, antigen binding scaffolds, and carbohydrates.
7. The compound of claim 6, wherein L is an antibody or a fragment thereof.
8. The compound of claim 7, wherein L is an antibody or fragment thereof that specifically binds a tumor associated antigen,
9. The compound of claim 7, wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with Z2.
10. The compound of clam 1 , wherein Z2 is represented by the following structural formula:
-Z2A-Z2B-Z2C-¾D-:
wherein:
Z2A, 2B, Z2C and Z2D are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5¾-, -0-, -C(=0)-, -0-C(=0)-, -C(=O)-0-, -O-C(=0)-O-, -C(=0)-(C¾)pl)
Figure imgf000070_0002
-(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, - C(=S , -C(=S)-S-, -C(=S>NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR -, -N(Rt)- C(=0)-N(Rg)-, -N(R4)-C(=0)0-, -N(R )-C{=0)-, -C(=0)-N(R4 , -C(=0)-N(R4 C(=0 , -O-
Figure imgf000071_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyi, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Re, Rs are as defined in claim 1.
1 1. The compound of claim 10, wherein the antibody or a fragment thereof comprises a sulfur group that is covalently attached with Z2A-
12. The compound of clam 1 , wherein Zi is represented by the following structural formula:
Figure imgf000071_0002
wherein:
]A> IB, Zic and Zm are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyi, an aryl, a heteroaryl, a heterocyclyl, -CRsRe-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, ~C(=0)-(CHx)pi, -C(=0)-0-(CHx)pl, -(CHx)pl-C(=0)-, -(CHx)Pi-C(=0)-O5 -(0-(CH2)p2-)P3-! -((ΟΗ2)ρ2-0-)ρ3-3 - C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(R4> C(=0)-N( e , -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4)-, C(=0)-N(R4)-C(=0)-, -O-
or
Figure imgf000071_0003
wherein alkyl, alkynyl, alkenyl, cycloalkyi, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Re, Rs are as defined in claim 1.
13. The compound of claim 1 , wherein D is covalently attached with i
14. The compound of claim 1, wherein A is an amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, argi ine, serine, threonine, valine, tryptophan, tyrosine, cysteine, and citmlline.
15. The compound of claim 1, wherein A is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine- asparagine, asparagine-valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine- citrulline, alanine-asparagine, asparagine- alanine.
16. d from the group consisting of
Figure imgf000072_0001
wherein 9, Rio, Rn, and R12 are each independently H, an alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, R13R14, nitro, cyano, -OH, -0-C(=0)-Ri5, -C(=0)-R]5, -
Figure imgf000072_0002
further wherein, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri3 and R]4 are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl.
17.
Figure imgf000072_0003
(III)
wherein: Ab is an antibody or a fragment thereof;
AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulline-vaiine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagme-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-aspai'agine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagitie-citrulline, alanine-asparagine, asparagine-alanine;
a is an integer from 1 to 10
q is 0 or art integer from 1 to 5;
A3, i and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alk nyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CRsRe-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(0)-(CHx)pi-, -C(=0)-0-(C¾)Pi-, -(C¾)pi-C(=0)-, -(CHx)p,-C(=0)-0-, -(0-(CH2)p2-)p3-, -((C¾)p2-0-)p3-, -C(=S>, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(R4 C(=0)-N(R8)-, -N(R4)-C(=0)0-, -N(R )-C(=0)-, -ϋ(=Ο)-Ν0¾)-, -C(=0)-N(R4)-C(=0)-} -O- C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aiyl, heteroaryl, and heterocyclyl are optionally substituted;
R17 is selected from the group consisting of O, S, NRig, CR5R6 ;
R4, R5, R¾ and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
R9, Rio, R11, and R12 are each independently H, halogen, NR13R14, nitro, cyano, -OH, -
Figure imgf000073_0001
R)4! substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
R)3 and R14 are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and
DM is represented by the following structure:
Figure imgf000074_0001
18. The compound of claim 17,
wherein:
q is 4;
R-i and R3 are each independently -0-, -S-, NR4, -CR5R6-;
Ri7 is selected from the group consisting of O, S, Μ½, CR5¾ ;
Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, Rs^RsR , Rio, R11, R12 are each independently H or alkyl; and
A3 is an alkyl.
19. :
Figure imgf000074_0002
wherein Ab is an antibody or a fragment thereof. 20, The compound of formula (IV):
Figure imgf000075_0001
wherein:
Ab is an antibody or a fragment thereof;
AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine-asparagine, serine-asparagine, asparagine- serine, phenyialanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine- sparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine- alanine ;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5;
Rj is absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-s -O- C(=0)-, -C(=0)-0, -0-C(=0 0-, -C(=0)-(CHx)pl-, -C(=0)-0-(C¾)pl-, -(CHx)pl-C(=0)-, -
Figure imgf000075_0002
-S- C(=S)-, -S-C(=S)-S-, -S-, -SO-, -SO2-, -NR4-, -N(R4)-C(=0)-N(R8)-, -N(R4)-C(=0)0-, - N(R4)-C(=0)-, -C(=0)-N(R4)-, -C(=0)-N(R4 C(=0)-} -0-C(=0)- R4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
R4, is H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
Rg, Rio, Rn, and Ru are each independently H, halogen, NR13R14, nitro, cyano, -OH, - 0-C(=0)-R15, -C(=0)-Rls, -C(O)-0-Ri5, -C(=0)-NR13 R)4; substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
DM is represented by the following structure:
Figure imgf000076_0001
The compound of claim 20,
wherein:
q is 4; and
Ri is selected from the group consisting of -0-, -S-, NR4, and -CR5R6-; and further wherein R4, Rs, an ¾ are each independently H or alkyl.
Figure imgf000076_0002
wherein Ab is an antibody or a fragment thereof.
23. The compound of claim 1 , wherein A is a peptide cleavable by a protease.
24. The compound of claim 1 , wherein A is a peptide cleavable by a protease expressed in tumor tissue.
25. The compound of claim 24, wherein the protease is a cathepsin or a plasmin.
26. The pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients.
27. A method of reducing, retarding or stopping an abnormal cell growth comprising contacting the abnormal cell with a compound of claim 1, in an amount sufficient to retard, reduce or stop the abnormal cell growth, and wherein the abnormal cell growth is retarded, reduced or stopped.
28. A method of killing a cell, comprising contacting the cell with a compound of claim 1 , in an amount sufficient to kill the cell, and wherein the cell is killed.
29. The method of claim 28, wherein the cell is a tumor cell.
30. A method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound of claim 1.
31. The method of claim 30, wherein the individual is a mammal.
32. The method of any one of claims 30-31, further comprising administering sequentially or consecutively an additional therapy.
33. The method of claim 32, wherein additional therapy is radiation therapy, chemotherapy, or a combination of both.
34. The method of any one of claims 30-31, further comprising administering at least one additional therapeutic agent.
35. The method of claim 30, wherein the medical disorder is selected from the group consisting of tumors, cancers, infectious diseases, neurodegenerative diseases, bone disorders, and cardiovascular diseases.
36. A method of reducing tumor size, stopping tumor size increase, reducing tumor proliferation, or preventing tumor proliferation in an individual in need thereof comprising administering to the individual an effective amount of a composition to reduce tumor size, stop tumor size increase, reduce tumor proliferation, or prevent tumor proliferation, wherein the composition comprises a compound of claim 1.
37. A compound of Formul a (V)
Foimula (V)
Z2 A W X Y D wherein:
Z2 and Zi are each independently absent or a spacer;
D is a Biologically Active Molecule;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CRsRe-, or -NR4-;
X is absent, or a substituted or unsubstituted: aryl, heteroaryl, cycloalkyl, hetero
Figure imgf000078_0001
wherein Ai, A3, Ri and 3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5Rs-, -0-, -C(=0 , -0-C(=0)-, -C(=0 0, -0-C(=0)-0, -C(=0> (CH pi-,
Figure imgf000078_0002
-(0-(CH2)p2-)p3-, - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-} -S-, -SO-, -S02-, - R4-, -N(R4)-C(=0)-N(R8)-, -N(R4)-C(=0)0-, -N(R4)-C(=0>, -C(=0)-N(R4)-, -C(=0 N(R4)-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRig-, -CR5Re-;
i7 is selected from the group consisting of O, S, NRis, CR5R6; Rig is selected from the group consisting of H, alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted;
R4, R5, 6 and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100; and
x is 0, 1 or 2.
38. The compound of claim 37,
wherein:
Z2 is represented by Formula (VII):
-Z2A-Z2B-Z2C-Z2D- (VII)
further wherein:
Z2A, Z2B, 2c and Z2D are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0 0-, -C(=0)-(CHK)pi,
Figure imgf000079_0001
-(0-(CH2)p2-)p3-, -((C¾)p2-0-)p3-, - C(=S>, -C(=S)-S-, -C(=S)- H-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(R4 C(=0)-N(R8)-, -N(R4)-C(=0)0-, -N(¾)-C(=0)-, -C(=0)-N(R4)-, -C(=0)-N(R4)-C(=0)-, -O-
C(=0)-N(R4),
Figure imgf000079_0002
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, Re, Rg are as defined in claim 37;
Zi is represented by Formula (VIII):
-Z1A-ZIB-Z1C-Z1D- (VIII)
wherein:
ZIA> ZiB, Zic and ZID are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR≤R6-, -0-, -C(=0 , -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pi,
Figure imgf000079_0003
-(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, - C(=S , -C(=S)-S-5 -C(=S)-NH-, -S-C(=S)-S -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -N(R4 =0)-N(R8)-, -N(R4>C(=0)0-, -N(R4 C(0 . -C(=0>N(R4>, -C(=0)-N(R4)-C(=0 , -O-
Figure imgf000080_0001
wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, Rs, Re, Rg are as defined in claim 37;
A is a peptide selected from the group consisting of valine-citrulHne, citrulline-valine, lysine- phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine- asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine- phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine- asparagine, asparagine- isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine- glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine- alanine;
Figure imgf000080_0002
wherein R9, R10, n, and R12 are each independently H, an alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halogen, NR13R14, nitro, cyano, -OH,
Figure imgf000080_0003
- C(=0)-0-R15, -C(=0>NRi3 Ri4,
further wherein, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
Ri3 and R14 are each independently H or an optionally substituted alkyl; and R] 5 is an optionally substituted alkyl; and
ansinoid of Formula II:
Figure imgf000080_0004
wherein: Αβ, A , Ag, A are each independently absent, an amino acid, N-alkyl amino acid, a peptide having 2-20 amino acids, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5F -, -0-, -C(=0)-, -0-C(=0)-, -C(O)-0-, -0-C(=0)-0-, - C(=0)-(C¾)pl, -C(=0)-0-(CHx)pl, -(C¾)pl-C(=0)-, -(C¾)p,-C(=0)-0-, -(0-(C¾)p2-)P3-, - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -
Figure imgf000081_0001
N(R4 C(=0)-, 0-C(=0)-NR4, further wherein alky], alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and R4, R5, ¾, g are as defined in claim 37.
The compound of claim 38, wherein the maytansinoid is represented by the following
Figure imgf000081_0002
The compound of claim 3 , having the structure:
Figure imgf000081_0003
Figure imgf000082_0001
41. A compound of formula (IX) :
Formula (IX)
Y, Zy D
wherein:
D is a Biologically Active Molecule;
Figure imgf000082_0002
further wherein R.3a and A3a are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloaikyl, an aryl, a heteroaryl, a heterocyclyl, -CR5¾-, -0-, -C(=0 , -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)- (C¾)pi-, -C(=0)-0-(CHx)pl-, -(CHx)pl-C(=0)-, -(CHx)pl-C(=0)-0-, -(0-(CH2)P2-)P3"3 - ((CH2)p2-0-)p3-, -C(=S>, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -
Figure imgf000083_0001
N(R4)-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycloalkyi, aryl, heteroaryl, and heterocyclyl are optionally substituted; and
i is represented by the following structural formula:
-Z1A-Z1B-Z1C-Z1D-,
wherein:
¾A, ¾B, ic and ID are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyi, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0>, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0)-(CHx)pl,
Figure imgf000083_0002
-(0-(CH2)p2-)p3-, -((CH2)p2-0-)p3-, - C(=S , -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -S02-, -NR4-, -Ν(1¾ =0)-N(R8 , -N( 4 C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N(R4 , C(=0)-N(R4>C(=0)-, -O-
Figure imgf000083_0003
wherein alkyl, alkynyl, alkenyl, cycloalkyi, aryl, heteroaryl, and heterocyclyl are optionally substituted and R4, R5, e and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
42. The compound of claim 41 wherein IC50 of the compound is greater than about 10 nM.
43. The compound of claim 41 wherein the compound is about 10 fold less cytotoxic than the corresponding compound of claim 1.
44. A compound of formula (X):
Figure imgf000084_0001
wherein:
Ab is an antibody or a fragment thereof;
a is an integer from 1 to 10;
Z2 and Zi are each independently absent or a spacer;
A is a natural or non-natural amino acid, or a peptide comprising 2-20 amino acids; W is absent, -0-, -S-, -CR5R<5-, -NR4-;
X is absent, aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein aryl, heteroaryl, cyclo
Figure imgf000084_0002
wherein Ai, A3, Ri and R3 are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an aikenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, -CR5R6-, -0-, -C(=0 , -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, -C(=0> (CHx)pl-, -C(=0)-0-(CHx)pl-, -(CHx)pl-C(=0)-, -(C¾)pl-C(=0)-0-, -(0-(CH2)p2-)p3-, - ((CH2)p2-0-)p3-, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -SO,-, - NR -, -N(R )-C(=0)-N(R8)-, -N(R4)-C(=0)0-, -Ν(¾ (=0 , -C(=0)-N(R4>, -C(=0 N(R4)-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, alkynyl, aikenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
A4 and A5 are each independently -0-, -S-, -NRi s-: -CR5 6-;
Ri7 is selected from the group consisting of O, S, NRig, CR5R&;
is is selected from the group consisting of H, alkyl, alkynyl, aikenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl, wherein alkyl, alkynyl, aikenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, and acyl are optionally substituted; R4, R5, Re and Rs are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and
Figure imgf000085_0001
wherein a is an integer from 1 to 10.
46. A compound of formula (XI):
Figure imgf000085_0002
wherein:
Ab is an antibody or a fragment thereof;
AA1-AA2 is a peptide selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine- valine, threonine- sparagine, serine- sparagine, asparagine-serine, phenyialanine-asparagine, asp aragine-phenyl alanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid- asparagine, asparagine-glutamic acid, citruiHne-asparagme, asparagine-citrulline, alanine-asparagine, asparagine-alanine ;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5;
A3, Ri and Rj are each independently absent, an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclylheterocyclyl, -CR5R6-, -0-, -C(=0)-, -0-C(=0)-, -C(=0)-0-, -0-C(=0)-0-, - C(=0)-(C¾)pl-, -C(=0)-0-(C¾)pl-, -(C¾)pl-C(=0)-, -(CHx)pl-C« )-0, -(0-(CH2)p2-)p3-, -((CH2)prO-)p3-, -C(=S , -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, -SO , -NR4-, -N(R4)-C(=0)-N(Rs)-3 -N(R4)-C(=0)0-, -N(R4)-C(=0)-, -C(=0)-N( 4)-, -C(=0)- N(R )-C(=0)-, -0-C(=0)-NR4-, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
R17 is selected from the group consisting of O, S, NRjs, CR5R0;
R4, R5, Re and Rg are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
Rg, Rio, Rn, and R12 are each independently H, halogen, RI3RH, nitro, cyano, -OH, -
Figure imgf000086_0001
3 R , substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;
Ri3 and H are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl;
pi, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2; and
llowing structure:
Figure imgf000086_0002
The compound of claim 46 represented by the following structure:
Figure imgf000087_0001
wherein a is an integer from 1 to 10.
PCT/US2014/029757 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses WO2014145090A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CA2902872A CA2902872A1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
CN201480025356.9A CN105188766B (en) 2013-03-15 2014-03-14 Bioactive molecule, its conjugate and therapeutical uses
SG11201507481WA SG11201507481WA (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
JP2016503215A JP6847388B2 (en) 2013-03-15 2014-03-14 Bioactive molecules, their conjugates, and therapeutic uses
MA38496A MA38496B2 (en) 2013-03-15 2014-03-14 Biologically active molecules, their conjugates, and therapeutic uses
EP21194635.5A EP3964237A1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
BR112015022585-3A BR112015022585B1 (en) 2013-03-15 2014-03-14 COMPOUND, PHARMACEUTICAL COMPOSITION, DRUG-ANTIBOD CONJUGATE, AND USE THEREOF
MX2015011348A MX2015011348A (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses.
AU2014233385A AU2014233385C1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
EA201500905A EA038512B1 (en) 2013-03-15 2014-03-14 Maytansinoid conjugates and therapeutic use thereof
NZ710814A NZ710814B2 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
EP14729755.0A EP2968593A1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
MYPI2015002247A MY183572A (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
KR1020157028418A KR102306490B1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
US14/776,668 US10570151B2 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
IL240418A IL240418B (en) 2013-03-15 2015-08-06 Biologically active molecules, conjugates thereof, and therapeutic uses
ZA2015/05813A ZA201505813B (en) 2013-03-15 2015-08-13 Biologically active molecules, conjugates thereof, and therapeutic uses
PH12015502131A PH12015502131A1 (en) 2013-03-15 2015-09-15 Biologically active molecules, conjugates thereof, and therapeutic uses
HK16100789.7A HK1212890A1 (en) 2013-03-15 2016-01-25 Biologically active molecules, conjugates thereof, and therapeutic uses
US16/740,312 US11345715B2 (en) 2013-03-15 2020-01-10 Biologically active molecules, conjugates thereof, and therapeutic uses
US17/733,974 US20220332729A1 (en) 2013-03-15 2022-04-29 Biologically active molecules, conjugates thereof, and therapeutic uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792216P 2013-03-15 2013-03-15
US61/792,216 2013-03-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,668 A-371-Of-International US10570151B2 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses
US16/740,312 Division US11345715B2 (en) 2013-03-15 2020-01-10 Biologically active molecules, conjugates thereof, and therapeutic uses

Publications (1)

Publication Number Publication Date
WO2014145090A1 true WO2014145090A1 (en) 2014-09-18

Family

ID=50933481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029757 WO2014145090A1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses

Country Status (19)

Country Link
US (3) US10570151B2 (en)
EP (2) EP3964237A1 (en)
JP (3) JP6847388B2 (en)
KR (1) KR102306490B1 (en)
CN (1) CN105188766B (en)
AU (1) AU2014233385C1 (en)
BR (1) BR112015022585B1 (en)
CA (1) CA2902872A1 (en)
CL (1) CL2015002765A1 (en)
EA (1) EA038512B1 (en)
HK (1) HK1212890A1 (en)
IL (1) IL240418B (en)
MA (1) MA38496B2 (en)
MX (1) MX2015011348A (en)
MY (1) MY183572A (en)
PH (1) PH12015502131A1 (en)
SG (1) SG11201507481WA (en)
WO (1) WO2014145090A1 (en)
ZA (1) ZA201505813B (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138460A1 (en) 2014-03-11 2015-09-17 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
US9302015B2 (en) 2013-08-21 2016-04-05 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2016160615A1 (en) * 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2018058003A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9950076B2 (en) 2016-01-25 2018-04-24 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
WO2018093866A1 (en) 2016-11-16 2018-05-24 Regeneron Pharmaceuticals, Inc. Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
WO2018159582A1 (en) 2017-02-28 2018-09-07 学校法人近畿大学 Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
WO2018237335A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
US10449258B2 (en) 2015-06-09 2019-10-22 Xdcexplorer (Shanghai) Co., Ltd. Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof
WO2019212965A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US10487149B2 (en) 2016-04-01 2019-11-26 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
WO2020172475A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
US10881743B2 (en) 2017-12-06 2021-01-05 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US10913800B2 (en) 2018-12-21 2021-02-09 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
WO2021055895A1 (en) 2019-09-19 2021-03-25 Regeneron Pharmaceuticals, Inc. Anti-ptcra antibody-drug conjugates and uses thereof
US10994020B2 (en) 2017-01-06 2021-05-04 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
WO2021151031A1 (en) 2020-01-24 2021-07-29 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
WO2021174113A1 (en) 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
US11110180B2 (en) 2017-10-04 2021-09-07 Avidity Biosciences Inc. Nucleic acid-polypeptide compositions and uses thereof
US20210275685A1 (en) * 2018-06-26 2021-09-09 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
US11129903B2 (en) 2015-07-06 2021-09-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US11142767B2 (en) 2017-07-21 2021-10-12 The Governors Of The University Of Alberta Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
WO2022014698A1 (en) 2020-07-17 2022-01-20 第一三共株式会社 Method for producing antibody-drug conjugate
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US11446387B2 (en) 2020-03-27 2022-09-20 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
WO2022211075A1 (en) 2021-03-31 2022-10-06 日本マイクロバイオファーマ株式会社 Method for manufacturing antibody-drug conjugate and enzyme used for same
US11525137B2 (en) 2020-03-19 2022-12-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11578090B2 (en) 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11596635B2 (en) 2013-08-26 2023-03-07 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US11912779B2 (en) 2021-09-16 2024-02-27 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8542802B2 (en) 2007-02-15 2013-09-24 Global Tel*Link Corporation System and method for three-way call detection
TW201836647A (en) 2017-04-06 2018-10-16 美商艾伯維有限公司 Anti-prlr antibody-drug conjugates (adc) and uses thereof
JP7364471B2 (en) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド Cyclodextrin protein drug conjugate
JP7426931B2 (en) * 2017-11-07 2024-02-02 レゲネロン ファーマシューティカルス，インコーポレーテッド Hydrophilic linkers for antibody drug conjugates
KR20240027578A (en) 2021-04-05 2024-03-04 알테이아 사이언스 에스.알.엘. Diagnosis and treatment of myeloid disorders and acute leukemia using novel tumor-specific antigens
WO2023194501A1 (en) 2022-04-05 2023-10-12 Altheia Science S.R.L. Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005089808A2 (en) 2004-03-15 2005-09-29 Wyeth Antibody calicheamicin conjugates
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
WO2007002222A2 (en) 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates
US20070037972A1 (en) 2005-08-09 2007-02-15 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
US20080171040A1 (en) 2004-06-01 2008-07-17 Genentech, Inc. Antibody-drug conjugates and methods
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US20080305497A1 (en) 2007-05-23 2008-12-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
WO2009134977A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
WO2010010324A1 (en) 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules
US20100129314A1 (en) 2008-04-30 2010-05-27 Immunogen Inc. Potent conjugates and hydrophilic linkers
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
WO2011018611A1 (en) 2009-08-10 2011-02-17 Ucl Business Plc Reversible covalent linkage of functional molecules
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
US20120096572A1 (en) 2010-08-02 2012-04-19 Regeneron Pharmaceuticals, Inc. Mice That Make VL Binding Proteins
WO2012166559A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US20130029900A1 (en) * 2011-06-21 2013-01-31 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013053873A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
WO2013053872A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
US20130101546A1 (en) 2011-06-10 2013-04-25 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2014065661A1 (en) * 2012-10-23 2014-05-01 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
DK1487493T3 (en) * 2002-03-01 2010-05-25 Univ Tulane Conjugates of cytotoxic agents and biologically active peptides
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1639092B1 (en) 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
JP5196654B2 (en) * 2005-06-20 2013-05-15 ジェネンテック， インコーポレイテッド Compositions and methods for tumor diagnosis and treatment
JP5394246B2 (en) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド Antibodies and immunoconjugates and methods for their use
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
WO2009126934A2 (en) * 2008-04-11 2009-10-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
CA2757382A1 (en) * 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
MX2012003198A (en) * 2009-10-23 2012-06-12 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods.
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
MX339739B (en) 2010-09-01 2016-06-07 Bayer Ip Gmbh N-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamides and use thereof as herbicides.
EA201390575A1 (en) 2010-10-29 2014-01-30 Иммьюноджен, Инк. NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES
WO2012061590A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
EP2640727B1 (en) * 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CN108524510A (en) 2011-05-16 2018-09-14 皇家飞利浦有限公司 bio-orthogonal drug activation
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
KR20150023027A (en) 2012-06-19 2015-03-04 폴리테릭스 리미티드 Novel Process for Preparation of Antibody Conjugates and Novel Antibody Conjugates
NO2789793T3 (en) 2012-10-24 2018-01-27
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
CN103254213B (en) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 Preparation method of maytenin-like ester and composition used in method
CN104688740A (en) 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 Related maytansine derivatives and preparation method and application thereof
KR102306490B1 (en) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. Biologically active molecules, conjugates thereof, and therapeutic uses
CN103254311B (en) 2013-05-09 2015-05-13 齐鲁制药有限公司 Method for preparing antibody-maytansine alkaloid medicine conjugate
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
KR102252925B1 (en) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
WO2015081281A1 (en) 2013-11-26 2015-06-04 Segway Orthopaedics, Inc. Surgical blade with viewing aperture
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
CN105793268B (en) 2013-12-02 2019-03-15 香港浸会大学 There are two the cancer resistance Caulis Mayteni chlorins compounds for condensing big ring for tool
CN106573074B (en) 2014-06-02 2022-04-12 里珍纳龙药品有限公司 Bioactive molecule conjugates, reagents and methods of preparation and therapeutic uses thereof
CN107995912A (en) 2015-03-27 2018-05-04 里珍纳龙药品有限公司 CHROMATOGRAPHIC FRACTIONATION AND MASS derivative, its conjugate and application method
SG11201806322QA (en) 2016-01-25 2018-08-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2005089808A2 (en) 2004-03-15 2005-09-29 Wyeth Antibody calicheamicin conjugates
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US20080171040A1 (en) 2004-06-01 2008-07-17 Genentech, Inc. Antibody-drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
WO2007002222A2 (en) 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates
US20070037972A1 (en) 2005-08-09 2007-02-15 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US20080305497A1 (en) 2007-05-23 2008-12-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US20100129314A1 (en) 2008-04-30 2010-05-27 Immunogen Inc. Potent conjugates and hydrophilic linkers
WO2009134977A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
WO2010010324A1 (en) 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules
WO2011018611A1 (en) 2009-08-10 2011-02-17 Ucl Business Plc Reversible covalent linkage of functional molecules
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
US20120096572A1 (en) 2010-08-02 2012-04-19 Regeneron Pharmaceuticals, Inc. Mice That Make VL Binding Proteins
WO2012166559A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US20130101546A1 (en) 2011-06-10 2013-04-25 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates
US20130029900A1 (en) * 2011-06-21 2013-01-31 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013053873A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
WO2013053872A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2014065661A1 (en) * 2012-10-23 2014-05-01 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AGARWAL ET AL., PROC. NATL. ACAD. SCI., USA, vol. 110, 2013, pages 46 - 51
CARRICO ET AL., NAT. CHEM. BIOL., vol. 3, 2007, pages 321 - 322
DUBOWCHIK ET AL., BIOCONJUGATE CHEM., vol. 13, 2002, pages 855
HAMBLETT, CANCER RES., vol. 10, 2004, pages 7063
HOFER ET AL., PROC. NATL. ACAD. SCI., USA, vol. 105, 2008, pages 12451 - 12456
HOLLANDER ET AL., BIOCONJUGATE CHEM,, vol. 19, 2008, pages 358 - 361
J. A. DAVIS ET AL: "In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates", DRUG METABOLISM AND DISPOSITION, vol. 40, no. 10, 29 June 2012 (2012-06-29), pages 1927 - 1934, XP055135213, DOI: 10.1124/dmd.112.046169 *
J. A. REDDY ET AL: "Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate", CANCER RESEARCH, vol. 67, no. 13, 1 July 2007 (2007-07-01), pages 6376 - 6382, XP055135216, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-3894 *
JEFFREY S C ET AL: "Dipeptide-based highly potent doxorubicin antibody conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 2, 15 January 2006 (2006-01-15), pages 358 - 362, XP027965900, ISSN: 0960-894X, [retrieved on 20060115] *
KING ET AL., J. AM. CHEM. SOC., vol. 114, no. 8, 1992, pages 3033
LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
MARNETT ET AL., J. MED. CHEM., vol. 39, 1996, pages 1692 - 1703
RABUKA ET AL., NAT. PROTOCOLS, vol. 10, 2012, pages 1052 - 1067
RYAN ET AL., FOOD & AGRICULTURE IMMUNOL., vol. 13, 2001, pages 127 - 130
SHAUNAK ET AL., NAT. CHEM. BIOL., vol. 2, 2006, pages 312 - 313
WHITESIDES ET AL., J. ORG. CHEM., vol. 56, 1991, pages 2648 - 2650
WIDDISON ET AL., J. MED. CHEM., vol. 49, 2006, pages 4392 - 4408
WIDDISON ET AL., J. MED. CHEM., vol. 49, no. 14, 2006, pages 4392 - 408
WIDDISON ET AL., J. MED. CHEM., vol. 49, no. 14, 2006, pages 4392 - 4408
WIDDISON ET AL., J. MED. CHEM., vol. 49, no. 14, 2006, pages 4401

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US11345715B2 (en) 2013-03-15 2022-05-31 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US10106616B2 (en) 2013-08-21 2018-10-23 Regeneron Pharmaceuticals, Inc. Antagonist antibodies to human prolactin receptor (PRLR)
US9302015B2 (en) 2013-08-21 2016-04-05 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
US9688764B2 (en) 2013-08-21 2017-06-27 Regeneron Pharmaceuticals, Inc. Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
US10683354B2 (en) 2013-08-21 2020-06-16 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells
US11596635B2 (en) 2013-08-26 2023-03-07 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
US9475875B2 (en) 2014-03-11 2016-10-25 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
US11608380B2 (en) 2014-03-11 2023-03-21 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
EA035809B1 (en) * 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. ANTI-EGFRvIII ANTIBODIES AND USES THEREOF
US10738124B2 (en) 2014-03-11 2020-08-11 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
WO2015138460A1 (en) 2014-03-11 2015-09-17 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
US10047160B2 (en) 2014-03-11 2018-08-14 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
US10752690B2 (en) 2014-06-02 2020-08-25 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
AU2016243527B2 (en) * 2015-03-27 2021-04-29 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
JP2018516851A (en) * 2015-03-27 2018-06-28 レゲネロン ファーマシューティカルス，インコーポレーテッド Maytansinoid derivatives, conjugates thereof, and methods of use
CN107995912A (en) * 2015-03-27 2018-05-04 里珍纳龙药品有限公司 CHROMATOGRAPHIC FRACTIONATION AND MASS derivative, its conjugate and application method
WO2016160615A1 (en) * 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
EA034950B1 (en) * 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Maytansinoid derivatives, conjugates thereof, and methods of use
KR102708103B1 (en) 2015-03-27 2024-09-20 리제너론 파아마슈티컬스, 인크. Maytansinoid derivatives, conjugates thereof, and methods of use
JP2021113191A (en) * 2015-03-27 2021-08-05 レゲネロン ファーマシューティカルス，インコーポレーテッド Maytansinoid derivatives, conjugates thereof, and methods of use
KR20170131587A (en) * 2015-03-27 2017-11-29 리제너론 파아마슈티컬스, 인크. Maytansinoid derivatives, conjugates thereof, and methods of use
US10449258B2 (en) 2015-06-09 2019-10-22 Xdcexplorer (Shanghai) Co., Ltd. Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof
US11191844B2 (en) 2015-07-06 2021-12-07 Regeneran Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US11129903B2 (en) 2015-07-06 2021-09-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
JP2019502746A (en) * 2016-01-25 2019-01-31 レゲネロン ファーマシューティカルス，インコーポレーテッド Maytansinoid derivatives, conjugates thereof, and methods of use
US11446389B2 (en) 2016-01-25 2022-09-20 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US9950076B2 (en) 2016-01-25 2018-04-24 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US10463749B2 (en) 2016-01-25 2019-11-05 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US10787519B2 (en) 2016-04-01 2020-09-29 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US10800848B2 (en) 2016-04-01 2020-10-13 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US10487149B2 (en) 2016-04-01 2019-11-26 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US10550188B2 (en) 2016-04-01 2020-02-04 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
WO2018058003A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
EP4273172A2 (en) 2016-09-23 2023-11-08 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
WO2018067331A1 (en) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates
US11142578B2 (en) 2016-11-16 2021-10-12 Regeneron Pharmaceuticals, Inc. Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
WO2018093866A1 (en) 2016-11-16 2018-05-24 Regeneron Pharmaceuticals, Inc. Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
US10925971B2 (en) 2016-11-29 2021-02-23 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
US10994020B2 (en) 2017-01-06 2021-05-04 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US11400163B2 (en) 2017-01-06 2022-08-02 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US11179472B2 (en) 2017-01-06 2021-11-23 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US12064483B2 (en) 2017-01-06 2024-08-20 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US11311627B1 (en) 2017-01-06 2022-04-26 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2018159582A1 (en) 2017-02-28 2018-09-07 学校法人近畿大学 Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
US10335496B2 (en) 2017-06-23 2019-07-02 VelosBio Inc. ROR1 antibody immunoconjugates
WO2018237335A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
US11142767B2 (en) 2017-07-21 2021-10-12 The Governors Of The University Of Alberta Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
US11891603B2 (en) 2017-07-21 2024-02-06 The Governors Of The University Of Alberta Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
US11110180B2 (en) 2017-10-04 2021-09-07 Avidity Biosciences Inc. Nucleic acid-polypeptide compositions and uses thereof
US11364302B1 (en) 2017-10-04 2022-06-21 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11583591B2 (en) 2017-12-06 2023-02-21 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11872287B2 (en) 2017-12-06 2024-01-16 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11246941B2 (en) 2017-12-06 2022-02-15 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11253607B2 (en) 2017-12-06 2022-02-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11497814B2 (en) 2017-12-06 2022-11-15 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11554176B2 (en) 2017-12-06 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11576980B2 (en) 2017-12-06 2023-02-14 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US10881743B2 (en) 2017-12-06 2021-01-05 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11712478B2 (en) 2017-12-06 2023-08-01 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US12037411B2 (en) 2018-04-30 2024-07-16 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
WO2019212965A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US20210275685A1 (en) * 2018-06-26 2021-09-09 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
US10913800B2 (en) 2018-12-21 2021-02-09 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
US11028179B2 (en) 2018-12-21 2021-06-08 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
US11834510B2 (en) 2018-12-21 2023-12-05 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
WO2020172475A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
US11578090B2 (en) 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021055895A1 (en) 2019-09-19 2021-03-25 Regeneron Pharmaceuticals, Inc. Anti-ptcra antibody-drug conjugates and uses thereof
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2021151031A1 (en) 2020-01-24 2021-07-29 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
WO2021174113A1 (en) 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
US11958910B2 (en) 2020-02-28 2024-04-16 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
US11999955B2 (en) 2020-03-19 2024-06-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
US12049629B2 (en) 2020-03-19 2024-07-30 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US12104156B2 (en) 2020-03-19 2024-10-01 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
US11525137B2 (en) 2020-03-19 2022-12-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11707532B2 (en) 2020-03-27 2023-07-25 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
US11446387B2 (en) 2020-03-27 2022-09-20 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
WO2022014698A1 (en) 2020-07-17 2022-01-20 第一三共株式会社 Method for producing antibody-drug conjugate
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022211075A1 (en) 2021-03-31 2022-10-06 日本マイクロバイオファーマ株式会社 Method for manufacturing antibody-drug conjugate and enzyme used for same
US11912779B2 (en) 2021-09-16 2024-02-27 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
US12071485B2 (en) 2021-09-16 2024-08-27 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Also Published As

Publication number Publication date
JP2016521256A (en) 2016-07-21
JP2019135239A (en) 2019-08-15
CL2015002765A1 (en) 2016-06-24
AU2014233385B2 (en) 2019-03-07
ZA201505813B (en) 2023-01-25
US10570151B2 (en) 2020-02-25
JP2021105007A (en) 2021-07-26
EP3964237A1 (en) 2022-03-09
MX2015011348A (en) 2016-01-15
EP2968593A1 (en) 2016-01-20
US20160030591A1 (en) 2016-02-04
BR112015022585A2 (en) 2017-10-24
EA201500905A1 (en) 2017-02-28
MA38496B2 (en) 2021-01-29
BR112015022585B1 (en) 2023-04-04
IL240418A0 (en) 2015-09-24
PH12015502131B1 (en) 2016-01-25
KR102306490B1 (en) 2021-09-28
NZ710814A (en) 2020-10-30
US20220332729A1 (en) 2022-10-20
AU2014233385A1 (en) 2015-09-17
US11345715B2 (en) 2022-05-31
JP6847388B2 (en) 2021-03-31
CA2902872A1 (en) 2014-09-18
EA038512B1 (en) 2021-09-08
KR20150128932A (en) 2015-11-18
MY183572A (en) 2021-02-26
US20200277306A1 (en) 2020-09-03
IL240418B (en) 2020-11-30
MA38496A1 (en) 2018-06-29
CN105188766B (en) 2019-07-12
AU2014233385C1 (en) 2019-09-19
HK1212890A1 (en) 2016-06-24
CN105188766A (en) 2015-12-23
PH12015502131A1 (en) 2016-01-25
SG11201507481WA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US11345715B2 (en) Biologically active molecules, conjugates thereof, and therapeutic uses
US10752690B2 (en) Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
WO2019114666A1 (en) Bioactive conjugate, preparation method therefor and use thereof
ES2404304T3 (en) DM1 maitansinoid conjugates with trastuzumab antibody, bound by a non-cleavable linker, and its use in the treatment of tumors
EP3769787A1 (en) Conjugates of cysteine engineered antibodies
IL297167A (en) Charge variant linkers
WO2014134457A2 (en) Conjugates comprising cell-binding agents and cytotoxic agents
AU2017363237A1 (en) Selective sulfonation of benzodiazepine derivatives
JP6423804B2 (en) Complex containing cell binding agent and cytotoxic agent
NZ710814B2 (en) Biologically active molecules, conjugates thereof, and therapeutic uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480025356.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14729755

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 240418

Country of ref document: IL

Ref document number: 2014729755

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2902872

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/011348

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016503215

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15218147

Country of ref document: CO

Ref document number: 12015502131

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2014233385

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201506017

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 201500905

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20157028418

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 38496

Country of ref document: MA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015022585

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015022585

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150911